Document:

Exhibit 10.24

 EXHIBIT 10.24 

 

 

 2011 
 MANAGEMENT BONUS PLAN 
  
  

 
  
  

  
  

  

PURPOSE OF THE PLAN 

The Allergan, Inc. 2011 Management Bonus Plan (the “Plan”) is designed to reward eligible management-level employees for their
contributions to providing Allergan’s stockholders increased value for their investment through the successful accomplishment of specific financial objectives and individual performance objectives. 

 
  
 PLAN YEAR 
 The Plan year runs from January 1, 2011 through
December 31, 2011. 
  
  

ELIGIBILITY 

Unless otherwise provided in a written agreement between the Company and the applicable employee, and subject to the terms of the Plan,
you are eligible to participate in the Plan for the Plan year if you are: 
  

	•	 	 employed as a regular full-time or part-time employee of Allergan, Inc. and its subsidiaries (collectively, the “Company”) as of
June 30, 2011, 

  

	•	 	 in salary grades 7E and above, 

  

	•	 	 regularly scheduled to and work 20 or more hours per week, 

 

	•	 	 not covered by any other bonus or sales incentive plan (including the Executive Bonus Plan). 

 

	•	 	 actively employed by the Company on the date bonuses are paid (and are not on counseling review on such date) or you otherwise qualify for a
pro-rated bonus upon retirement, disability, death or layoff under the terms set forth below. Any employee who terminates for reasons other than those noted below will receive no bonus. 

Bonuses for the Plan year, if any, will be prorated for any participant who (i) becomes eligible to participate in the Plan after
the beginning of the Plan year, (ii) retires on or after his or her “normal retirement” date (“normal retirement” is defined as termination of employment after the Plan participant has attained age 55, provided that such
participant has been employed by the Company for a minimum of 5 years), (iii) becomes disabled, (iv) dies or (v) transfers into a position covered by another incentive plan. Notwithstanding the foregoing, a participant will receive no
bonus in cases of normal retirement or termination that, in either case, the Company determines in its sole discretion to be (a) by mutual agreement, (b) due to performance issues or (c) for serious misconduct. Bonuses, if any, for
any participant who is laid-off will be prorated provided the participant was eligible to participate in the Plan for at least six months of the Plan year. All proration will be based on the number of months of participation in the Plan during the
Plan year. 
 Notwithstanding anything in this Plan to the contrary, any individual who (a) performs services for the
Company and is classified or paid as an independent contractor (regardless of his or her classification for federal tax or other legal purposes) by the Company or (b) performs services for the Company pursuant to an agreement between the
Company and any other person or entity (e.g. a leasing organization) shall not be eligible to participate in the Plan. 

  
  

11 MBP    Page -1- 

  

PERFORMANCE OBJECTIVES 
 Bonuses under the Plan are determined based on both corporate performance and individual performance in relation to pre-established objectives, as follows: 

CORPORATE OBJECTIVES 
  

	¿	 Earnings Per Share (“EPS”)—EPS is defined as adjusted net earnings from continuing operations as measured by Wall Street
divided by the weighted average number of common and common equivalent shares on a diluted basis. 

  

	¿	 Revenue Growth in Local Currency—Net sales stated in constant local currency compared to the prior year. Specifically defined as the
percentage change in annual net sales in constant local currency from the previous fiscal year end to the current fiscal year end (“Revenue Growth”). The purpose of net sales stated in constant local currency is to remove any impact on net
sales growth from changes in currency exchange rates from year to year. 

  

	¿	 Research and Development (“R&D”) Reinvestment Rate—R&D expense as a percentage of revenue. Specifically defined as the
total annual R&D expense as a percentage of annual net sales as of the current fiscal year end. 

  

	¿	 Operating Income—Operating Income compared to budget may be considered for allocation of bonus pool amounts by Business Unit/Function.
Operating Income is defined as Net Sales minus Cost of Goods minus Selling and General Administrative expenses minus Research & Development minus allocated corporate interest where applicable. 

INDIVIDUAL OBJECTIVES 

Management Bonus Objectives (“MBOs”) are prepared by each participant and his or her supervisor at the beginning of the Plan
year and may be modified throughout the year as necessary. Objectives should reflect major results and accomplishments to be achieved in order to meet short and long-term business goals that contribute to increased stockholder value. MBOs are
expressed as specific, quantifiable measures of performance in relation to key operating decisions for the participant’s business unit, such as managing inventory levels, receivables, expenses, payables, increasing sales, eliminating
unnecessary capital expenditures, etc. 
 At the end of the Plan year, the supervisor evaluates the participant’s
performance in relation to his or her objectives in order to determine the size of the bonus award, if any. A more detailed description of how the award is calculated is provided under “Individual Bonus Award Calculation.” 

 
  
 BONUS POOL CALCULATION 
 The components of this calculation for the
bonus pool amount are: (1) EPS, (2) Revenue Growth and (3) R&D Reinvestment Rate. 
 Bonus pool amount 

Bonuses become payable when the Company achieves a threshold level of 
 target EPS performance. The bonus pool is determined by EPS performance, 
 Revenue
Growth and R&D Reinvestment Rate as outlined in the table below. 

  
  

11 MBP    Page -2- 

																					
	Earnings Per Share	  	 	  	Revenue
Growth	  	 	  	R&D Reinvest
Rate	  	 	  	 
	 	 	 		 	 		 	 		 
	 EPS

Range%
	  	
EPS Range    	  	
Bonus % of    
Target	  	 	  	
Revenue
Growth	  	
Bonus % of    
Target	  	 	  	
R&D
Reinvest
Rate	  	
Bonus % of    
Target	  	 	  	Bonus % of    
Target
	 		 		 	 		 	 		 
	 -4.2%
	  	-$0.150	  	0.0%	  		  		  	 	  		  		  	 	  		  	0.0%
	 		 		 	 		 	 		 
	 -2.2%
	  	-$0.080	  	46.0%	  		  	3.7%	  	0.0%	  		  	14.85%	  	0.0%	  		  	46.0%
	 		 		 	 		 	 		 
	 -1.9%
	  	-$0.070	  	57.0%	  		  	4.7%	  	2.0%	  		  	15.10%	  	2.0%	  		  	61.0%
	 		 		 	 		 	 		 
	 -1.3%
	  	-$0.045	  	68.0%	  		  	5.7%	  	4.0%	  		  	15.35%	  	4.0%	  		  	76.0%
	 		 		 	 		 	 		 
	 -1.0%
	  	-$0.035	  	72.0%	  		  	6.7%	  	6.0%	  		  	15.60%	  	6.0%	  		  	84.0%
	 		 		 	 		 	 		 
	 -0.6%
	  	-$0.020	  	76.0%	  		  	7.7%	  	8.0%	  		  	15.85%	  	8.0%	  		  	92.0%
	 		 		 	 		 	 		 
	 	  	Target	  	80.0%	  		  	8.7%	  	10.0%	  		  	16.10%	  	10.0%	  		  	100.0%
	 		 		 	 		 	 		 
	 0.8%
	  	$0.030	  	84.0%	  		  	9.7%	  	13.8%	  		  	16.35%	  	13.8%	  		  	111.5%
	 		 		 	 		 	 		 
	 1.7%
	  	$0.060	  	88.0%	  		  	10.7%	  	17.5%	  		  	16.60%	  	17.5%	  		  	123.0%
	 		 		 	 		 	 		 
	 2.2%
	  	$0.080	  	92.0%	  		  	11.7%	  	21.3%	  		  	16.85%	  	21.3%	  		  	134.5%
	 		 		 	 		 	 		 
	
2.8%
	  	$0.100	  	96.0%	  		  	12.7%	  	25.0%	  		  	17.10%	  	25.0%	  		  	146.0%

Revenue Growth and R&D Reinvestment Rate components of the bonus pool may not exceed target unless EPS performance is
equal to or greater than target. If actual results fall between the performance levels shown above, bonuses will be prorated accordingly. For sake of clarity, if the Company’s performance exceeds any of the targets for Revenue Growth and/or
R&D Reinvestment Rate, but EPS does not exceed the threshold level of target EPS performance, no bonus will be payable. 
 BONUS POOL
DIFFERENTIATION BY BUSINESS UNIT/FUNCTION 
  

	¿	 Operating Income—The target bonus pool determined by EPS, Revenue Growth and R&D Reinvestment Rate performance may be modified for
each business unit/function based on Operating Income results vs. budget. That is, a business unit that exceeds budget may receive a greater share of the total Company pool than a business unit that is below budget. 

At the end of the year, the Company’s Chief Executive Officer may recommend adjustments to the bonus pool levels to the Organization
and Compensation Committee (the “Committee”) after consideration of key operating results. When calculating corporate performance for purposes of this Plan, the Committee has the discretion to include or exclude any or all of the following
items: 
  

	 	•	 	 extraordinary, unusual or non-recurring items; 

  

	 	•	 	 effects of accounting changes; 

  

	 	•	 	 effects of financing activities; 

  

	 	•	 	 expenses for restructuring or productivity initiatives; 

 

	 	•	 	 other non-operating items; 

  

	 	•	 	 spending for acquisitions; 

  

	 	•	 	 effects of divestitures; 

  

	 	•	 	 amortization of acquired intangible assets; and 

  

	 	•	 	 any other items of significant income or expense which are determined to be appropriate adjustments. 

  
  

11 MBP    Page -3- 

  

INDIVIDUAL BONUS AWARD CALCULATION 
 Target bonus awards are expressed as a percentage of the participant’s eligible earnings for the Plan year (as determined by the Compensation department in its discretion). The target percentages
vary by salary grade (see Attachment No. 1). A participant’s actual bonus award may vary above or below the targeted level based on the supervisor’s evaluation of his or her performance in relation to the predetermined MBOs. Except as
may otherwise be approved by the Committee, each participant’s actual bonus award may be modified down to 0% or up to 150% of his or her target bonus amount. However, the total of all bonus awards given within each business unit must total no
more than 100% of the total bonus pool dollars allocated to that business unit. 
  

 
 METHOD OF PAYMENT 

Except as may otherwise be approved by the Committee, for participants who are subject to a Company executive stock ownership guideline,
any bonus will be paid in cash up to a maximum amount equal to 100% of the participant’s bonus targets and the portion of the bonus attributable to performance over such targets is paid in restricted stock or restricted stock units with cliff
vesting two years from the award effective date. Any payment in the form of restricted stock or restricted stock units will be issued under the Company’s 2008 Incentive Award Plan, as amended, restated, modified, supplemented or superseded.
Upon a recipient’s normal retirement eligibility date (defined as the date on which the recipient has (i) attained age 55 and (ii) been employed by the Company for a minimum of 5 years) all of the restrictions imposed on the
recipient’s restricted stock shall lapse or the recipient’s restricted stock units shall vest, as applicable. 
 For
all other participants, any bonus will be paid in cash. Bonus awards are paid following the close of the Plan year after the review and authorization of bonuses by the Committee. 

Bonuses will be paid within 30 days following management communication of the award, with cash bonuses paid through the participant’s
normal payroll channel. In the event of a Change in Control (as defined in Attachment No. 2), bonuses will be paid within 30 days of the effective date of the Change in Control. 

 
  
 CHANGE IN CONTROL 
 If a Change in Control occurs after the close of
the Plan year and Company performance supports bonus pool payment, participants will be paid a bonus based on performance in relation to the EPS, Revenue Growth and R&D Reinvestment Rate targets. 

If the Change in Control occurs during the Plan year, participants will be paid a bonus prorated to the effective date of the Change in
Control and EPS, Revenue Growth and R&D Reinvestment Rate performance will be deemed to be the greater of: 
  

	 	•	 	 100% of the EPS, Revenue Growth and R&D Reinvestment Rate targets; or 

 

	 	•	 	 the prorated actual year-to-date performance. 

 In either case, a participant’s actual bonus may vary above or below the targeted level according to the provisions outlined in “Individual Bonus Award Calculation” above. Participants must
be employed by the Company or its successor on the effective date of the Change in Control in order to receive the prorated payment, unless their employment is terminated by reason of retirement, death or disability or if it is determined that any
such participant is terminated without cause in connection with the Change in Control. For purposes of this Plan, “cause” shall be limited to only three types of events: the willful refusal to comply with a lawful, written

  
  

11 MBP    Page -4- 

 
instruction of the Company’s Board of Directors so long as the instruction is consistent with the scope and responsibilities of the participant’s position prior to the Change in
Control; dishonesty which results in a material financial loss to the Company (or to any of its affiliated companies) or material injury to its public reputation (or to the public reputation of any of its affiliated companies); or conviction of any
felony involving an act of moral turpitude. 
  
  

SECTION 409A 
 Any bonuses that become payable under this Plan to participants who are subject to U.S. federal income taxes are intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as
amended (“Section 409A”), as short-term deferrals within the meaning of Treasury Regulation section 1.409A-1(b)(4), and this Plan shall be administered and construed consistent with this intent. For purposes of the foregoing, any bonus
that becomes payable to such a participant shall be paid no later than the 15th day of the third month following the end of the later of (i) the participant’s first taxable year in which the participant’s right to receive such bonus is no longer subject to a
“substantial risk of forfeiture” (within the meaning of Section 409A) or (ii) the Company’s first taxable year in which the participant’s right to receive such bonus is no longer subject to a substantial risk of
forfeiture. 
  
  
 GENERAL 
 Management reserves the right to define corporate
performance and individual performance, to interpret the Plan document to make factual determinations under the Plan in its sole discretion, and to review, alter, amend, or terminate the Plan at any time subject to approval of the Committee. This
Plan does not constitute a contract of employment and cannot be relied upon as such. Any questions regarding this Plan should be directed to the Human Resources department or the Vice President, Global Compensation and Benefits. This Plan document
supersedes any previous document you may have received. 

  
  

11 MBP    Page -5- 

 ATTACHMENT NO. 1 

ALLERGAN 

 

2011 MANAGEMENT BONUS PLAN 

 TARGET AWARDS 
  

					
	 	  	US	 	Intl
			
	Salary Grade / Title	  	Target Bonus	 	Target Bonus
			
	 7E
	  	15%	 	20%
			
	 8E
	  	20%	 	25%
			
	 9E
	  	25%	 	30%
			
	 10E
	  	30%	 	35%
			
	 11E
	  	40%	 	40%
			
	 12E
	  	40%	 	45%
			
	 13E
	  	45%	 	50%
			
	 14E
	  	55%	 	
			
	 EVP, General Counsel & Assistant Secretary
	  	55%	 	
			
	 EVP, Human Resources
	  	55%	 	
			
	 EVP, Global Technical Operations
	  	60%	 	
			
	 EVP, R&D, Chief Scientific Officer
	  	75%	 	
			
	 EVP, Finance & Business Development, CFO
	  	75%	 	

  
  

11 MBP    Page -6- 

 ATTACHMENT NO. 2 

CHANGE IN CONTROL DEFINITION 
 “Change in Control” shall mean the following and shall be deemed to occur if any of the following events occur: 

(a) Any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) (a “Person”), who becomes the “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act or any successor rule (a “Beneficial Owner”), directly or indirectly, of
securities of Allergan, Inc., a Delaware corporation (“Allergan”) representing (i) 20% or more of the combined voting power of Allergan’s then outstanding voting securities, which acquisition is not approved in advance of the
acquisition or within 30 days after the acquisition by a majority of the Incumbent Board (as hereinafter defined) or (ii) 33% or more of the combined voting power of Allergan’s then outstanding voting securities, without regard to whether
such acquisition is approved by the Incumbent Board; or 
 (b) Individuals who, as of the date hereof,
constitute the Board of Directors of Allergan (the “Incumbent Board”), cease for any reason to constitute at least a majority of the Board of Directors, provided that any person becoming a director subsequent to the date hereof whose
election, or nomination for election by Allergan’s stockholders, is approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption
of office is in connection with an actual or threatened election contest relating to the election of the directors of Allergan) shall be considered as though such person were a member of the Incumbent Board of Allergan; or 

(c) The consummation of a merger, consolidation or reorganization involving Allergan, other than one which satisfies
both of the following conditions: 
 (1) a merger, consolidation or reorganization which would result in the
voting securities of Allergan outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of another entity) at least 55% of the combined voting power of the voting
securities of Allergan or such other entity resulting from the merger, consolidation or reorganization (the “Surviving Corporation”) outstanding immediately after such merger, consolidation or reorganization and being held in substantially
the same proportion as the ownership in Allergan’s voting securities immediately before such merger, consolidation or reorganization, and 
 (2) a merger, consolidation or reorganization in which no Person is or becomes the Beneficial Owner directly or indirectly, of securities of Allergan representing 20% or more of the combined voting power
of Allergan’s then outstanding voting securities; or 
 (d) The stockholders of Allergan approve a plan of
complete liquidation of Allergan or an agreement for the sale or other disposition by Allergan of all or substantially all of Allergan’s assets. 
 Notwithstanding the preceding provisions, a Change in Control shall not be deemed to have occurred if the Person described in the preceding provisions is (1) an underwriter or underwriting syndicate
that has acquired the ownership of any of Allergan’s then outstanding voting securities solely in connection with a public offering of Allergan’s securities, (2) Allergan or any subsidiary of Allergan or (3) an employee stock
ownership plan or other employee benefit plan maintained by Allergan (or any of its affiliated companies) that is qualified under the provisions of the Internal Revenue Code of 1986, as amended. In addition, notwithstanding the preceding provisions,
a Change in Control shall not be deemed to have occurred if the Person described in the preceding provisions becomes a Beneficial Owner of more than the permitted amount of outstanding securities as a result of the acquisition of voting securities
by Allergan which, by reducing the number of voting securities outstanding, increases the proportional number of shares beneficially owned by such Person, provided, that if a Change in Control would occur but for the operation of this sentence and
such Person becomes the Beneficial Owner of any additional voting securities (other than through the grant or issuance of securities pursuant to an award (e.g., stock option grant, restricted stock award, restricted stock unit award) granted by the
Company, or through a stock dividend or stock split), then a Change in Control shall occur. 

  
  

11 MBP    Page -7-Exhibit 10.55

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 EXHIBIT 10.55

 COLLABORATION AGREEMENT 
 BY AND AMONG 
 MAP PHARMACEUTICALS, INC., 

ALLERGAN SALES, LLC, 
 ALLERGAN USA, INC. 
 AND 

ALLERGAN, INC. 
 January 28, 2011 

 TABLE OF CONTENTS 

Page 

									
			
	1.	 	 DEFINITIONS
	  	 	1	  
			
	2.	 	 LICENSE GRANT
	  	 	13	  
				
		 	2.1	  	 License Grant to ALLERGAN
	  	 	13	  
				
		 	2.2	  	 Sublicense Rights
	  	 	13	  
				
		 	2.3	  	 Certain Restrictions
	  	 	13	  
				
		 	2.4	  	 Canada Option.
	  	 	14	  
				
		 	2.5	  	 No Implied Rights or Licenses
	  	 	14	  
				
		 	2.6	  	 Sublicensed Rights
	  	 	14	  
			
	3.	 	 GOVERNANCE
	  	 	14	  
				
		 	3.1	  	 Committees Generally
	  	 	14	  
				
		 	3.2	  	 Joint Steering Committee
	  	 	15	  
				
		 	3.3	  	 Alliance Managers
	  	 	16	  
				
		 	3.4	  	 Product Development Committee
	  	 	17	  
				
		 	3.5	  	 Joint Commercialization Committee
	  	 	19	  
			
	4.	 	 DEVELOPMENT
	  	 	20	  
				
		 	4.1	  	 Development Responsibilities
	  	 	20	  
				
		 	4.2	  	 Development Plans
	  	 	21	  
				
		 	4.3	  	 Subcontracting Permitted
	  	 	21	  
				
		 	4.4	  	 Clinical Data
	  	 	22	  
				
		 	4.5	  	 Costs
	  	 	22	  
				
		 	4.6	  	 Efforts
	  	 	22	  
			
	5.	 	 REGULATORY MATTERS
	  	 	22	  
				
		 	5.1	  	 Preparation and Ownership of Regulatory Materials
	  	 	22	  
				
		 	5.2	  	 Notice of Communication with Regulatory Authorities
	  	 	22	  
				
		 	5.3	  	 Pharmacovigilance and Safety Monitoring Activities
	  	 	23	  
				
		 	5.4	  	 Risk Evaluation and Mitigation Strategies (“REMS”)
	  	 	24	  
				
		 	5.5	  	 Costs
	  	 	24	  
				
		 	5.6	  	 Product Recall
	  	 	24	  
			
	6.	 	 COMMERCIALIZATION
	  	 	24	  
				
		 	6.1	  	 Commercialization
	  	 	24	  

  
 i 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

									
		 	6.2	  	 Commercialization Plans.
	  	 	25	  
				
		 	6.3	  	 Sales Force Efforts
	  	 	26	  
				
		 	6.4	  	 PDE Expense Cap
	  	 	27	  
				
		 	6.5	  	 MAP Sales Force
	  	 	27	  
				
		 	6.6	  	 Packaging; Promotional Materials
	  	 	27	  
				
		 	6.7	  	 Costs
	  	 	27	  
				
		 	6.8	  	 Efforts
	  	 	28	  
				
		 	6.9	  	 Commercialization of Other Products
	  	 	28	  
			
	7.	 	 MANUFACTURING AND DISTRIBUTION
	  	 	28	  
				
		 	7.1	  	 General
	  	 	28	  
				
		 	7.2	  	 Costs
	  	 	28	  
			
	8.	 	 PAYMENT OBLIGATIONS
	  	 	29	  
				
		 	8.1	  	 Upfront Payment
	  	 	29	  
				
		 	8.2	  	 Milestone Payments
	  	 	29	  
				
		 	8.3	  	 Sharing of Distributable Profit and Loss
	  	 	29	  
				
		 	8.4	  	 Accounting and Reporting of Net Sales and Shared Expenses
	  	 	30	  
				
		 	8.5	  	 Process, Reports and Financial Reconciliation
	  	 	30	  
				
		 	8.6	  	 Currency of Payment
	  	 	32	  
				
		 	8.7	  	 Withholding
	  	 	33	  
				
		 	8.8	  	 Initial Indication Costs and Expenses Prior to First Commercial Sale
	  	 	33	  
				
		 	8.9	  	Additional Required Indication and Additional Collaboration Indication Development Cost and Expense Cap.	  	 	33	  
			
	9.	 	 RECORD RETENTION AND AUDITS
	  	 	33	  
				
		 	9.1	  	 Record Retention
	  	 	33	  
				
		 	9.2	  	 Audit Request
	  	 	33	  
			
	10.	 	 INVENTIONS, KNOW-HOW AND
PATENTS
	  	 	34	  
				
		 	10.1	  	 Existing Intellectual Property
	  	 	34	  
				
		 	10.2	  	 Ownership of Inventions
	  	 	34	  
				
		 	10.3	  	 Patent Prosecution and Maintenance
	  	 	35	  
				
		 	10.4	  	 Patent Costs
	  	 	35	  
				
		 	10.5	  	 Third Party Infringement Claims
	  	 	36	  
				
		 	10.6	  	 Enforcement of MAP Patent Rights Against Third Parties
	  	 	36	  
				
		 	10.7	  	 Notice of Third Party Infringement Litigation
	  	 	37	  

  
 ii 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

									
		 	10.8	  	 Further Actions
	  	 	37	  
			
	11.	 	 TRADEMARKS
	  	 	37	  
			
	12.	 	 REPRESENTATIONS AND WARRANTIES
	  	 	38	  
				
		 	12.1	  	 The Parties’ Representations and Warranties
	  	 	38	  
				
		 	12.2	  	 Representations and Warranties of ALLERGAN
	  	 	40	  
				
		 	12.3	  	 Representations and Warranties of MAP
	  	 	40	  
			
	13.	 	 NON-SOLICITATION OF EMPLOYEES
	  	 	41	  
				
		 	13.1	  	 Non-Solicitation
	  	 	41	  
			
	14.	 	 MUTUAL INDEMNIFICATION AND INSURANCE
	  	 	41	  
				
		 	14.1	  	 MAP’s Right to Indemnification
	  	 	41	  
				
		 	14.2	  	 ALLERGAN’s Right to Indemnification
	  	 	42	  
				
		 	14.3	  	 Process for Indemnification
	  	 	42	  
				
		 	14.4	  	 Insurance
	  	 	43	  
			
	15.	 	 CONFIDENTIALITY.
	  	 	44	  
				
		 	15.1	  	 Confidentiality
	  	 	44	  
				
		 	15.2	  	 Degree of Care; Permitted Use
	  	 	44	  
				
		 	15.3	  	 Exceptions
	  	 	44	  
				
		 	15.4	  	 Permitted Disclosures
	  	 	45	  
				
		 	15.5	  	 Return of Confidential Information
	  	 	45	  
				
		 	15.6	  	 Public Disclosure
	  	 	45	  
			
	16.	 	 TERM AND TERMINATION
	  	 	46	  
				
		 	16.1	  	 Effective Date and Term
	  	 	46	  
				
		 	16.2	  	 Termination by ALLERGAN
	  	 	46	  
				
		 	16.3	  	 Termination by MAP
	  	 	46	  
				
		 	16.4	  	 Termination for Material Breach
	  	 	46	  
				
		 	16.5	  	 Challenge
	  	 	47	  
				
		 	16.6	  	 Consequences of Termination
	  	 	47	  
				
		 	16.7	  	 Surviving Obligations
	  	 	47	  
				
		 	16.8	  	 Accrued Rights, Surviving Obligations
	  	 	48	  
				
		 	16.9	  	 Rights in Bankruptcy
	  	 	48	  
			
	17.	 	 LIMITATION OF LIABILITY AND EXCLUSION
OF DAMAGES; DISCLAIMER OF WARRANTY
	  	 	48	  
			
	18.	 	 MISCELLANEOUS
	  	 	49	  

  
 iii

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

									
		 	18.1	  	 Agency
	  	 	49	  
				
		 	18.2	  	 Assignment
	  	 	49	  
				
		 	18.3	  	 Further Actions
	  	 	49	  
				
		 	18.4	  	 Force Majeure
	  	 	49	  
				
		 	18.5	  	 Notices
	  	 	50	  
				
		 	18.6	  	 Amendment
	  	 	50	  
				
		 	18.7	  	 Waiver
	  	 	51	  
				
		 	18.8	  	 Counterparts
	  	 	51	  
				
		 	18.9	  	 Construction
	  	 	51	  
				
		 	18.10	  	 Severability
	  	 	51	  
				
		 	18.11	  	 Governing Law
	  	 	51	  
				
		 	18.12	  	 Dispute Resolution; Exclusive Dispute Resolution Mechanism.
	  	 	51	  
				
		 	18.13	  	 Compliance with Applicable Laws
	  	 	52	  
				
		 	18.14	  	 Divestitures
	  	 	52	  
				
		 	18.15	  	 Entire Agreement
	  	 	53	  

  

			
	 EXHIBITS
	  	
		
	 EXHIBIT 1.7
	  	ALLERGAN Trademarks
		
	 EXHIBIT 1.29
	  	Co-Promotion Agreement
		
	 EXHIBIT 1.34
	  	Device
		
	 EXHIBIT 1.35
	  	Dihydroergotamine
		
	 EXHIBIT 1.63(a)
	  	MAP Patent Rights: [***]
		
	 EXHIBIT 1.63(b)
	  	MAP Patent Rights: [***]
		
	 EXHIBIT 1.63(c)
	  	MAP Patent Rights: [***]
		
	 EXHIBIT 1.67
	  	MAP Trademarks
		
	 EXHIBIT 1.96
	  	Press Release
		
	 EXHIBIT 1.113
	  	Shared Expenses
		
	 EXHIBIT 6.2(b)
	  	Signing Date TRx Forecast
		
	 EXHIBIT 8.3
	  	Example of Profit Share Calculation Under Section 8.3

  
 iv 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
		
	 EXHIBIT 8.5
	  	Example of Net Sales Calculation

  
 v 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 COLLABORATION AGREEMENT 

This Collaboration Agreement (the “Agreement”) is made and entered into as of the 28th day of January, 2011 (the “Effective Date”) by and
among MAP Pharmaceuticals Inc., a Delaware corporation having an address at 2400 Bayshore Parkway, Suite 200, Mountain View, California 94043 (“MAP”), Allergan USA, Inc., a Delaware corporation (“Allergan
USA”), Allergan Sales, LLC, a California limited liability corporation (“Allergan Sales”), and Allergan, Inc., a Delaware corporation (collectively with Allergan USA and Allergan Sales,
“ALLERGAN”), each having an address at 2525 Dupont Drive, Irvine, California 92612. MAP and ALLERGAN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 Recitals 
 Whereas, MAP is a biotechnology company engaged in the research, development and commercialization of products consisting of pharmaceutical compounds and devices for delivering such compounds;

 Whereas, ALLERGAN is engaged in the business of manufacturing, marketing, promoting, selling and distributing
pharmaceutical products; 
 Whereas, MAP is developing a product designated as LEVADEXTM, a
pharmaceutical product consisting of a proprietary formulation of dihydroergotamine delivered using MAP’s proprietary
TEMPO® delivery system; 
 Whereas, ALLERGAN and MAP desire to further develop and jointly commercialize LEVADEX in the United States (and to the extent set forth in this Agreement, Canada) to certain specialist physicians
for the treatment of migraines; and 
 Whereas, MAP will be responsible, itself or through third party manufacturers, for
the manufacture and supply of LEVADEX for such purposes. 
 Agreement 

Now, therefore, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound, agree as follows: 

1.     DEFINITIONS.  As used herein, the following terms shall have the following
meanings: 
 1.1     “Additional Collaboration Indications” means the Follow-On
Indications for which the Parties mutually agree in writing that the costs and expenses thereof are Allowable Development Expenses pursuant to Section 4.1(b) of this Agreement. 

  
 1 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.2     “Additional Required Indication” means
the treatment of migraine in adolescents twelve (12) to eighteen (18) years of age. 

1.3     “Affiliate” means a corporation, partnership, trust or other entity that directly, or
indirectly through one or more intermediates, controls, is controlled by or is under common control with a specified Party. For purpose of this definition, “control,” “controlled by” and “under common control with”
shall mean the possession of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting equity, voting member or partnership interests, control of a majority of the board of
directors or other similar body, by contract or otherwise. In the case of a corporation, the direct or indirect ownership of fifty percent (50%) or more of its outstanding voting shares or the ability otherwise to elect a majority of the board
of directors or other managing authority of the entity shall in any event be presumptively deemed to confer control, it being understood that the direct or indirect ownership of a lesser percentage of such shares shall not necessarily preclude the
existence of control. 
 1.4     “ALLERGAN Estimated Shared Expenses” has the
meaning set forth in Section 8.4(a). 
 1.5     “ALLERGAN Inventor” has the
meaning set forth in Section 10.2. 
 1.6     “ALLERGAN Shared Expenses Estimate
Report” has the meaning set forth in Section 8.4(a). 
 1.7     “ALLERGAN
Trademarks” means the Trademarks set forth on Exhibit 1.7. 
 1.8     “Alliance
Manager” has the meaning set forth in Section 3.3(a). 
 1.9     “Allowable
Development Expenses” means [***] expenses and the costs and expenses incurred by a Party or for its account [***] that are consistent with the approved Development Plan(s) and are specifically attributable to the Development of Product,
including without limitation [***] and [***], including without limitation [***], in each case, to the extent [***]. 

1.10     “Allowable Patent Expenses” means [***], recorded as an expense in accordance with
GAAP, and statutory fees incurred after the Effective Date in connection with the preparation, filing, prosecution, and maintenance (including the costs of ex parte or inter partes activities including patent interference, re-examination and
opposition proceedings) of Patents and Patent Applications in the Territory included in MAP Patent Rights that cover Product or its manufacture or use in the Field; provided, that [***] shall be subject to appropriate documentation verifying the
allocation of [***] on such activities. For purposes of clarification, [***]. 
 1.11    
“Allowable Pre-Approval Manufacturing Expenses” means all costs and expenses incurred prior to [***] associated with any [***], as set forth in Section 1.2 of Exhibit 1.113. 

  
 2 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.12     “Allowable Regulatory Expenses” means
all costs and expenses [***], including FDA user and other fees, [***] recorded as an expense in accordance with GAAP, by or on behalf of a Party or any of its Affiliates during the Term and pursuant to this Agreement, that are specifically
attributable to the preparation of regulatory submissions for, and the obtaining and maintenance of Regulatory Approval of, Product in the Field in the Territory, including without limitation compliance with requirements of such Regulatory
Authorities, adverse event recordation and reporting, regulatory affairs activities, pharmacovigilance, post-approval safety monitoring, REMS programs and patient registries, in each case in the Territory, and in each case excluding [***].

 1.13     “Applicable Laws” means all applicable statutes, ordinances, codes,
executive or governmental orders, laws (including common law), rules, and regulations, including without limitation any rules, regulations, guidelines or other requirements of Regulatory Authorities, that may be in effect from time to time.

 1.14     “Business Day” means a day other than Saturday, Sunday or any day on
which commercial banks located in the State of California, U.S.A., are authorized or obligated by Applicable Laws to close. 

1.15     “Calendar Quarter” means the respective periods of three (3) consecutive
calendar months ending on March 31, June 30, September 30 and December 31; provided, however, that (a) the first Calendar Quarter of the Term or following First Commercial Sale of Product shall extend from the
commencement of such period to the end of the first complete Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement. 

1.16     “Calendar Year” means (a) for the first year of the Term, the period beginning
on the Effective Date and ending on December 31, 2011, (b) for each year of the Term thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31, and
(c) for the last year of the Term, the period beginning on January 1 of the year in which the Agreement expires or terminates and ending on the effective date of expiration or termination of this Agreement. 

1.17     “Canada” has the meaning set forth in Section 2.4. 

1.18     “Canada Option” has the meaning set forth in Section 2.4. 

1.19     “Chemistry, Manufacturing and Controls” or “CMC” means the part of
pharmaceutical development that is directed to the manufacture of Device, DHE and Compound, the specifications therefor, and other process parameters which indicate that the manufacturing process is consistent and controlled. 

1.20     “Clinical Trials” means Phase I Clinical Trials, Phase II Clinical Trials, Phase III
Clinical Trials, Phase IV Clinical Trials, and/or variations of such trials (e.g., Phase II/III). 

  
 3 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.21     “Commercialization” means all
activities undertaken relating to the marketing and/or offering for sale of Product to physicians and their patients, including without limitation advertising, education, planning, marketing, promotion, market and product support and sales
representative Detailing. Commercialization does not include the right to book sales of or sell Product. “Commercialize” shall have a corresponding meaning. 
 1.22     “Commercialization Plan” has the meaning set forth in Section 6.2(a). 
 1.23     “Commercially Reasonable Efforts” means, with respect to the Development, Manufacture and/or Commercialization of Product and any other activities
conducted under the Agreement with respect to Product, the level of efforts and resources (including without limitation the promptness with which such efforts and resources would be applied) commonly used in the pharmaceutical industry by a company
of similar size and experience, or by the respective Party with respect to a product of similar commercial potential at a similar stage in its development or product life. If a Party has other products in its portfolio for the same indication as
Product, then Commercially Reasonable Efforts shall require the relevant Party to apply efforts to Product no less favorable in the aggregate than what it applies to any other product for the same indication as Product. 

1.24     “Competing Product” means any pharmaceutical product (other than Product) that is
used to treat acute migraine; provided, that in no event shall [***] be considered a Competing Product. 

1.25     “Compound” means the mesylate salt form of dihydroergotamine in a formulation for
delivery by Inhalation. 
 1.26     “Confidential Disclosure Agreement” has the
meaning set forth in Section 15.1. 
 1.27     “Confidential Information” has
the meaning set forth in Section 15.1. 
 1.28     “Control” means, with
respect to any item of Information, Patent, know-how or other intellectual property right, the right to grant a license or sublicense with respect thereto as provided for in this Agreement, without violating the terms of any agreement or other
arrangement with, or any legal rights of, or without requiring the consent of or payment to, any Third Party. 

1.29     “Co-Promotion Agreement” means the Co-Promotion Agreement, in the form attached
hereto as Exhibit 1.29, entered into by the Parties as of the date of this Agreement. 
 1.30    
“Current Good Manufacturing Practices” or “cGMP” means the regulations set forth in 21 C.F.R. Parts 210–211, 820, and 21 C.F.R. Subchapter C (Drugs), Quality System Regulations and the requirements thereunder
imposed by the FDA, and, as applicable, any similar or equivalent regulations and requirements in jurisdictions outside the United States. 

  
 4 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.31     “Detail” means a presentation for
Product by a sales representative during a face-to-face meeting with a Physician Target in an individual or group practice setting (not including dinner meetings, medical conventions, medical education meetings, sample drops or incidental contacts)
in which the FDA-approved indicated uses, safety, effectiveness, contraindications, side effects, warnings, and other relevant characteristics of Product are described in a fair and balanced manner consistent with the requirements of Applicable Laws
and the requirements of the United States Food, Drug and Cosmetic Act, as amended, including, but not limited to, the regulations of 21 C.F.R. § 202, in an effort to increase the number of Physician Targets prescribing Product, and/or the
number of prescriptions for Product. “Detailing” shall have a corresponding meaning. 

1.32     “Development” means all activities relating to obtaining Regulatory Approval of
Product, or assisting in broadening the label for Product or the ability to market Product, including, for example, preclinical testing, toxicology, formulation, Clinical Trials, and regulatory affairs, as well as any and all such activities
conducted following Regulatory Approval, including, but not limited to, Clinical Trials to explore Follow-On Indications. “Develop” shall have a corresponding meaning. 

1.33     “Development Plan” has the meaning set forth in Section 4.2(a). 

1.34     “Device” means MAP’s proprietary TEMPO pressurized metered dose inhaler. The
current embodiment of the Device is described on Exhibit 1.34. Unless otherwise noted, the use of the term “Device” in this Agreement is not intended to indicate thereby the definition of “device” in the Federal Food, Drug and
Cosmetic Act, as amended. 
 1.35     “Dihydroergotamine” or “DHE”
means the molecule set forth on Exhibit 1.35. 
 1.36     “Distributable Loss”
and “Distributable Profit” means the amount equal to (i) Net Sales of Product (if any) during the applicable reporting period, less (ii) Shared Expenses incurred during the applicable reporting period. There shall be a
Distributable Loss in a reporting period if subtracting the amount in (ii) from the amount of (i) results in a negative number, and a Distributable Profit if subtracting the amount in (ii) from the amount of (i) equals zero
(0) or results in a positive number. 
 1.37     “Distributable Loss Report”
and “Distributable Profit Report” have the meanings set forth in Section 8.5. 

1.38     “Dollar” means a U.S. dollar, and “$” shall be interpreted
accordingly. 
 1.39     “Effective Date” has the meaning set forth in
Section 16.2. 
 1.40     “Executives” has the meaning set forth in
Section 3.2(c). 
 1.41     “FDA” means the U.S. Food and Drug Administration,
or any successor thereto, having the administrative authority to regulate the marketing of human pharmaceutical products or biological therapeutic products, delivery systems and devices in the United States. 

  
 5 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.42     “Field” means the [***]. 

1.43     “First Commercial Sale” means the first arm’s length commercial sale of Product
to a Third Party who is not a Sublicensee (including without limitation any final sale to a distributor or wholesaler under any non-conditional sale arrangement). 
 1.44     “Follow-On Indication(s)” means additional indications for Product other than the Initial Indication. For clarity, Follow-On Indications include,
without limitation, the Additional Required Indication and the Additional Collaboration Indications. 

1.45     “FTE” means the equivalent of an employee or agent of MAP or ALLERGAN working one
thousand eight hundred and forty (1,840) labor hours per year on Manufacturing, Commercialization or Development of Product. 
 1.46     “FTE Costs” means, for each non-Sales Force FTE undertaking particular activities under this Agreement, equal to: (i) the FTE Rate for the
relevant employee or agent performing activities under this Agreement, multiplied by (ii) a number representing the portion of an FTE provided by such employee or agent that is directly allocable to the activities undertaken pursuant to this
Agreement (e.g., 0.5 for an employee or agent providing 50% of an FTE to activities under this Agreement). 

1.47     “FTE Rate” means, [***] 

1.48     “GAAP” means U.S. generally accepted accounting principles consistently applied.

 1.49     “IND” means any Investigational New Drug application, as defined in the
applicable regulations promulgated by the FDA, filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto. 
 1.50     “Information” means ideas, Inventions, discoveries, concepts, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets,
technology, designs, drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, data (including without limitation pharmacological, toxicological and clinical data, analytical and quality
control data, manufacturing data and descriptions, Patent and legal data, market data, financial data or descriptions), devices, assays, chemical formulations, specifications, compositions of matter, product samples and other samples, physical,
chemical and biological materials and compounds, and the like, in written, electronic or other form, now known or hereafter developed, whether or not patentable, and all improvements thereto. 

1.51     “Inhalation” means the delivery of an active pharmaceutical ingredient by oral
inhalation for systemic absorption via the lung. 
 1.52     “Initial Indication”
means treatment of acute migraine with or without aura in adults (humans who are eighteen (18) years or older) or such other initial indication for Product, as is first approved by the FDA. 

  
 6 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.53     “Initial Indication Approval” means
Regulatory Approval by the FDA for the Initial Indication of Product for use in the Field in the Territory. 

1.54     “Invention” means inventions as determined in accordance with U.S. patent law and
arising in the course of the Parties’ performance under the Agreement that employees, Sublicensees, Affiliates, independent contractors, or agents of one Party or both Parties solely or jointly make, conceive, reduce to practice or otherwise
discover. 
 1.55     “Joint Commercialization Committee” or “JCC”
has the meaning set forth in Section 3.4. 
 1.56     “Joint Steering
Committee” or “JSC” has the meaning set forth in Section 3.1. 

1.57     “Manufacture” or “Manufacturing” means the synthesis,
manufacturing, processing, formulating, packaging, labeling, holding and quality control testing of DHE, Compound, Device and Product. 
 1.58     “MAP Estimated Shared Expenses” has the meaning set forth in Section 8.4(a). 

1.59     “MAP Inventions” has the meaning set forth in Section 10.2. 

1.60     “MAP Know-How” means all Information that is (a) Controlled by MAP as of the
Effective Date or at any time during the Term that is not generally known and not readily ascertainable by proper means, even though parts thereof may be known, and (b) necessary or useful to develop, make, use, sell, offer for sale, import or
export Product for use in the Field in the Territory. For the avoidance of doubt, Information that is publicly disclosed by MAP or becomes generally known through no fault of ALLERGAN or breach of this Agreement shall no longer be included as part
of MAP Know-How. 
 1.61     “MAP Licensed Intellectual Property” shall mean the MAP
Patent Rights and MAP Know-How, licensed by MAP to ALLERGAN under Section 2.1, and MAP Trademarks, licensed by MAP to ALLERGAN under Section 11.2. 
 1.62     “MAP Operating Loss” and “MAP Operating Profit” means the amount equal to (i) Net Sales (if any) during the applicable reporting
period, less (ii) MAP Shared Expenses incurred during the applicable reporting period. There shall be a MAP Operating Loss in a reporting period if subtracting the amount in (ii) from the amount of (i) results in a negative number,
and a MAP Operating Profit if subtracting the amount in (ii) from the amount of (i) equals zero (0) or results in a positive number. 
 1.63     “MAP Patent Rights” means any rights granted by any governmental authority under any Patent and/or Patent Application Controlled by MAP as of the
Effective Date or at any time during the Term that claims an invention related to Product or the manufacture, use, sale, offering for sale, import or export of Product. MAP Patent Rights include [***]. 

  
 7 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.64     “MAP PCP Detail” means [***] targeting
PCPs in the Field in the Territory: [***]. 
 1.65     “MAP Sales Force” has the
meaning set forth in Section 6.4(b). 
 1.66     “MAP Shared Expenses Estimate
Report” has the meaning set forth in Section 8.4(a). 
 1.67     “MAP
Trademarks” means the Trademarks set forth on Exhibit 1.67. 
 1.68    
“Member” has the meaning set forth in Section 3.1. 
 1.69     “Member
Designee” has the meaning set forth in Section 3.1. 
 1.70     “Nektar
License” means the Restated and Amended License Agreement entered into by MAP and Nektar Therapeutics UK Limited dated August 7, 2006, as amended. 
 1.71     “Nektar Mark” means any trademark, trade name, brand name or logo of Nektar Therapeutics UK Limited as set forth in Sections 5 and 13.1 of the Nektar
License. 
 1.72     “Net Payment” has the meaning set forth in Section 8.5(d).

 1.73     “Net Sales” means, with respect to any applicable measurement period,
the amount determined in accordance with the following calculation: 
 [***] 

Where: 
 A
= [***]; 
 B = [***]; 
 C = [***]; 
 D = [***] 

 

	 	TMS =	 the amount invoiced by MAP or its Affiliate [***] to unaffiliated Third Parties, less the following deductions or allowances to the extent
actually taken, granted, or incurred by the selling entity: (a) normal and customary trade and/or quantity discounts actually allowed or taken, chargebacks, Medicaid/Medicare rebates (other than as described in (d) below), and allowances
actually taken; (b) sales, use, value added and excise taxes, import and customs duties, tariffs, and any other similar taxes, duties, tariffs, or other governmental charges to the extent included in the amount invoiced and not otherwise
reported as a Shared Expense; (c) freight, insurance, packaging costs, and other transportation charges to the extent included in the amount invoiced and not otherwise reported as a Shared Expense; (d) amounts repaid or credits taken by
reason of 

  
 8 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
rejections, outdating, defects, or returns or because of retroactive price reductions or due to recalls or government laws or regulations requiring rebate; and (e) any other items that
reduce gross sales amounts as required by GAAP applied on a consistent basis. “TMS” shall exclude any amount for Product furnished to a Third Party for which payment is not intended to be received, including but not limited to Product used
in Clinical Trials and Product distributed as promotional and free goods, in reasonable quantities. TMS will be determined in accordance with GAAP applied on a consistent basis. Sales between or among a Party or its Affiliates shall be excluded from
the computation of TMS, but the subsequent final sales to Third Parties by such Affiliates shall be included in the computation of TMS. 
 For purposes of calculating Net Sales, [***] included in A, B, C and D shall be as [***]. 
 1.74     “Net Sales Estimate Report” has the meaning set forth in Section 8.5. 
 1.75     “New Drug Application” or “NDA” means (a) the single application or set of applications for Product and/or pre-market approval to
make and sell commercially Product filed with the FDA, and (b) any related registrations with, or notifications to, the FDA. 
 1.76     “Other Physicians” means Physicians who are not Physician Targets or PCPs. 
 1.77     “Party” or “Parties” has the meaning set forth in the preamble of this Agreement. 

1.78     “Patent” means (a) letters patent (or other equivalent legal instrument),
including without limitation utility and design patents, and including any term adjustment, extension, substitution, registration, confirmation, reissue, re-examination, or renewal thereof and (b) all equivalents and foreign counterparts of any
of the foregoing. 
 1.79     “Patent Application” means an application for a
Patent, including without limitation any provisional application, reissue application, re-examination application, continuation application, continued prosecution application, continuation-in-part application, or a divisional application, and any
equivalent thereof. 
 1.80     “Patent Litigation Expenses” has the meaning set
forth in Section 10.6. 
 1.81     “Payment Adjustment” has the meaning set forth in
Section 8.5(c). 
 1.82     “PCPs” or “Primary Care
Physicians” means Physicians as defined by [***]. 
 1.83     “PCP Net
Sales” has the meaning set forth in Section 8.3(b). 
 1.84     “PCP Net Sales
Period” has the meaning set forth in Section 8.3(b). 

  
 9 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.85     “PDE” means a primary Detail equivalent
where (a) a Primary Detail for Product has a value of [***] primary Detail equivalent and (b) a Secondary Detail for Product has a value of [***] primary Detail equivalents; provided, however, that, [***]. 

1.86     “PDE Costs” means, for each PDE, an amount calculated by the product of PDE
multiplied by the PDE Rate. 
 1.87     “PDE Rate” means [***] per PDE [***].

 1.88     “PDUFA Date” means the date as set by the FDA for response to the NDA
pursuant to the Prescription Drug User Fee Act of 1992, as amended. 
 1.89     “Phase I
Clinical Trial” means any clinical study conducted on sufficient numbers of human subjects to establish that a pharmaceutical product is reasonably safe for continued testing and to support its continued testing in Phase II Clinical Trials.
Phase I Clinical Trial shall include without limitation any clinical trial that would or does satisfy requirements of 21 C.F.R. § 312.21(a), whether or not it is designated a Phase I Clinical Trial. 

1.90     “Phase II Clinical Trial” means any clinical study conducted on sufficient numbers
of human subjects that have the targeted disease of interest to investigate the safety and efficacy of a pharmaceutical product for its intended use and to define warnings, precautions, and adverse reactions that may be associated with such
pharmaceutical product in the dosage range to be prescribed. Phase II Clinical Trial shall include without limitation any clinical trial that would or does satisfy requirements of 21 C.F.R. § 312.21(b), whether or not it is designated a Phase
II Clinical Trial. 
 1.91     “Phase III Clinical Trial” means any clinical study
intended as a pivotal study for purposes of seeking Regulatory Approval that is conducted on sufficient numbers of human subjects to establish that a pharmaceutical product is safe and efficacious for its intended use, to define warnings,
precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, and to support Regulatory Approval of such pharmaceutical product or label expansion of such pharmaceutical product.
“Phase III Clinical Trial” shall include without limitation any clinical trial that would or does satisfy requirements of 21 C.F.R. § 312.21(c), whether or not it is designated a Phase III Clinical Trial. 

1.92     “Phase IV Clinical Trial” means clinical study of a pharmaceutical product on human
subjects commenced after receipt of Regulatory Approval of such pharmaceutical product for the purpose of satisfying a condition imposed by a Regulatory Authority to obtain Regulatory Approval, or to support the marketing of such pharmaceutical
product, and not for the purpose of obtaining initial Regulatory Approval of a pharmaceutical product. 

1.93     “Physician(s)” means any individual qualified and authorized by law to practice
medicine in a state, province, possession, protectorate or territory in the Territory. 
 1.94    
“Physician Targets” means Physicians [***]. 

  
 10 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.95     “Plan” means Development Plan or
Commercialization Plan, as applicable. 
 1.96     “Press Release” means the press
release set forth on Exhibit 1.96. 
 1.97     “Primary Detail” means, with respect
to a product, a detail (and with respect to Product, a Detail) made to healthcare professionals employed by or practicing at a given healthcare facility, in which a sales representative provides such information with respect to such product before
detailing another product. 
 1.98     “Prior Quarter” has the meaning set forth in
Section 8.5. 
 1.99     “Product” means a product that is a combination of
(a) the Compound, and (b) the Device. For clarity, Product excludes a Device sold alone or for use with an active ingredient that is not the Compound. 
 1.100     “Product Development Committee” or “PDC” has the meaning set forth in Section 3.3. 

1.101     “Product Launch Period” means the period beginning on the date
of the first shipment of Product to a wholesaler in the Territory and ending on December 31st of the following full Calendar Year. 
 1.102    
“Product Specifications” means the FDA-approved specifications for Product. 

1.103     “Promotional Materials” means all written, printed, electronic and graphic
materials intended for use in Detailing Product to Physician Targets for use in the Field in the Territory, including, but not limited to, visual aids, sales training materials, advertising, direct to consumer advertising, direct to physician
promotional materials, Product marketing brochures, internet materials, medical and scientific publications, file cards, premium items, clinical study reports, reprints, drug information updates, and any other promotional support items and all
product labels and inserts to be used by the Parties. 
 1.104     “Promotional, Sales,
Marketing, and Medical Affairs Expenses” or “PSMM Expenses” has the meaning as set forth in Exhibit 1.113. 
 1.105     “Quality Systems Regulations” means current quality systems regulations for medical products, as promulgated by the FDA, and the requirements
thereunder imposed by the FDA, or any more stringent standards required by Applicable Laws, including without limitation the regulations set forth in 21 C.F.R. Part 820 and equivalent Canadian Applicable Laws. 

1.106     “Recently Ended Quarter” has the meaning set forth in Section 8.5. 

1.107     “Regulatory Approval” means, with respect to a country or region in the Territory,
those approvals, licenses, registrations or authorizations of, by or with a Regulatory 

  
 11 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Authority necessary to commercially distribute, sell or market a product in such country, including, where applicable, (a) pricing or reimbursement approval in such country, (b) pre-
and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), (c) labeling approval and (d) technical, medical and scientific licenses necessary for commercial
distribution, sale or marketing of such product in such country. 
 1.108     “Regulatory
Authority” means any applicable supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities, including without limitation the FDA,
regulating or otherwise exercising authority with respect to the Commercialization of Product in the Field in the Territory. 

1.109     “Regulatory Materials” means any and all regulatory submissions, applications
(including but not limited to the NDA), regulatory reports, safety reports, registrations, filings, approvals and associated Drug Master File(s), label(s), labeling, package insert(s) and packaging and associated correspondence required to develop,
manufacture, market, sell and import Product in, or into, the Field in the Territory. 
 1.110    
“Sales Force” means each Party’s respective sales personnel Detailing to Physician Targets for use in the Field in the Territory that are qualified to do so pursuant to the terms and conditions of this Agreement and the
Co-Promotion Agreement. 
 1.111     “Sales Force Management Team” has the meaning
set forth in Section 6.5(a). 
 1.112     “Secondary Detail” means, with respect to
a product, a detail (and with respect to Product, a Detail) made to healthcare professionals employed by or practicing at a given healthcare facility, in which a sales representative provides such information with respect to such product after
detailing another product. 
 1.113     “Shared Expenses” means the costs and
expenses expressly set forth on Exhibit 1.113. 
 1.114     “sNDA” means a
supplemental New Drug Application for Product filed by MAP with the FDA, and (b) any related registrations with or notifications to the FDA. 
 1.115     “Sublicensee” means any person or entity to which either MAP grants a license or sublicense under the MAP Know-How or MAP Patents in the Field and in
the Territory (other than ALLERGAN) or ALLERGAN grants a sublicense under the license granted to ALLERGAN pursuant to this Agreement. 
 1.116     “Territory” means the United States and, if ALLERGAN exercises the Canada Option or the Parties otherwise mutually agree in writing that Canada shall
be included in the Territory, Canada. 

  
 12 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.117     “Third Party” means any person or
entity other than ALLERGAN, MAP, or an Affiliate of either of them. 
 1.118    
“Trademark” means any word, name, symbol, color, designation or device or any combination thereof, whether registered or unregistered, that is used (or intended to be used) in commerce to identify and distinguish one’s goods or
services from those manufactured or sold by others and to indicate the source of the goods or services, even if that source is unknown, including, without limitation, any trademark, trade dress, service mark, service name, brand mark, trade name,
brand name, logo, business symbol, or domain name. 
 2.     LICENSE
GRANT. 
 2.1     License Grant to ALLERGAN.   MAP hereby grants to
ALLERGAN a co-exclusive (with MAP) license, with the right to grant sublicenses in accordance with Section 2.2, under the MAP Know-How and MAP Patent Rights, to Commercialize Product solely to Physician Targets solely for use in the Field in
the Territory subject to and in accordance with the terms and conditions of this Agreement. For the avoidance of doubt, MAP shall have the exclusive right to Commercialize Product to Physicians that are not Physician Targets in the Territory. MAP
and ALLERGAN shall only exercise their co-exclusive Commercialization rights in accordance with the terms and conditions of this Agreement and the Co-Promotion Agreement. 
 2.2     Sublicense Rights.   ALLERGAN’s right to grant sublicenses under the license granted to it under Section 2.1 is subject to the prior written approval
of MAP, which approval shall not be unreasonably withheld, conditioned or delayed by MAP. Additionally, ALLERGAN shall require ALLERGAN’s permitted Sublicensees to agree in writing to be bound by all of the applicable terms and conditions of
this Agreement. ALLERGAN’s grant of any sublicense shall not relieve ALLERGAN from any of ALLERGAN’s obligations under this Agreement, and ALLERGAN shall remain jointly and severally liable for any uncured breach of a sublicense by a
Sublicensee of ALLERGAN to the extent that such uncured breach would constitute a breach of this Agreement. 

2.3     Certain Restrictions.   ALLERGAN agrees that (a) neither it, nor any of its Affiliates,
shall offer to sell or otherwise provide Product to any Third Party if ALLERGAN or its relevant Affiliates, knows, or has reason to believe, that Product offered for sale, sold or provided to such Third Party would be sold or transferred:
(i) outside the Territory; or (ii) for use outside the Field; and (b) it shall not use or practice under any intellectual property right licensed to it under this Agreement except as expressly permitted by this Agreement. ALLERGAN
agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from such actions described in Section 2.3(a) and (b). MAP agrees that, in the event that ALLERGAN is not granted rights in Canada
pursuant to Section 2.4, it will not offer to sell or otherwise provide Product to any Third Party in Canada if MAP knows, or has reason to believe, that Product offered for sale, sold or provided to such Third Party would be sold or
transferred into the United States. 

  
 13 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2.4     Canada Option. 

(a)     At anytime [***] after the Effective Date, ALLERGAN or its designated Affiliate, shall upon written notice to
MAP, have the right to exercise an option (the “Canada Option”), subject to the terms and conditions of this Agreement, relating to the respective roles and responsibilities of the Parties, to Commercialize Product to Physician
Targets in the Field in Canada, its provinces, possessions, protectorates and territories (“Canada”). 

(b)     Upon the exercise of the Canada Option, Canada shall be deemed to be included in the Territory. 

(c)     If ALLERGAN fails to exercise the Canada Option within the period specified in Section 2.4(a), ALLERGAN
shall for an additional [***] period thereafter (the “Canada Negotiation Period”) have a right of first negotiation for, on terms mutually agreed upon among the Parties, a license, with the right to grant sublicenses in accordance
with Section 2.2, under the MAP Know-How and MAP Patent Rights to Commercialize Product in Canada solely in the Field. The right of first negotiation granted hereunder shall be exercisable by ALLERGAN, or its designated Affiliate, upon written
notice to MAP and the Parties will use good faith efforts to reach agreement during the Canada Negotiation Period. In the event that the Parties do not reach agreement during the Canada Negotiation Period, then MAP shall be free to pursue
Commercialization of Product in the Field in Canada. 
 2.5     No Implied Rights or
Licenses.   MAP grants no additional rights or licenses in or to any Patent or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement.

 2.6     Sublicensed Rights.   Notwithstanding anything to the contrary in this
Agreement, the rights and licenses granted to ALLERGAN pursuant to this Agreement under MAP Know-How and MAP Patent Rights that are licensed to MAP pursuant to the Nektar License shall be subject to the terms and conditions of the Nektar License.

 3.     GOVERNANCE. 

3.1     Committees Generally.   The Parties shall form the committees described in this Article 3 to
oversee, coordinate and review recommendations and approve decisions for the Development, Regulatory Approval, Manufacture and Commercialization of Product to Physician Targets for use in the Field in the Territory. Each such committee shall be
comprised of four (4) voting members (each, a “Member”). Each Party shall have the right to appoint two (2) Members (each, a “Member Designee”) to serve on the each committee. Each Member Designee of the
JSC shall be a member of management of the appointing Party. The Member Designees of all other committees must be employees of the appointing Party. The following shall apply to each committee and its members: 

(a)     Each Party may replace its Member Designees at any time upon written notice to the other Party; 

  
 14 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b)     Each committee shall meet at least once every quarter at times
mutually agreed upon by the Parties, or more frequently as the Parties deem appropriate. At least two (2) such meetings per Calendar Year must be held in person, and all other such meetings may be held by teleconference or videoconference. The
location of the meetings to be held in person shall alternate between sites designated by each Party; 

(c)     The presence of at least one (1) MAP Member Designee and one (1) ALLERGAN Member Designee shall be
required to constitute a quorum at any meeting of a committee. No business shall be transacted at any meeting of a committee unless a quorum of the members of such committee is present at the time when the meeting proceeds to business; 

(d)     In addition to its Member Designees, the Parties shall have the right to invite observers to each meeting of
a committee. For meetings of the JSC, a Party must provide the other Party with advance written notice of such observers. Such observers shall not have any voting rights and shall be bound by written obligations of confidentiality and non-use,
either by virtue of his or her employment by such Party or by a separate written agreement; and 
 (e)    
Each Party shall be responsible for all travel and related costs and expenses for its Member Designees and other representatives to attend meetings of, and otherwise participate on any committee, and such costs and expenses will not be included in
Shared Expenses. 
 3.2     Joint Steering Committee. 

(a)     Formation; Purpose.   Within thirty (30) days of the Effective Date, the Parties will
establish a Joint Steering Committee (the “Joint Steering Committee” or “JSC”), which (i) shall oversee, coordinate and review recommendations and approve decisions for the Development, Regulatory
Approval, Manufacture and Commercialization of Product to Physician Targets for use in the Field in the Territory. The JSC shall coordinate the co-promotion of Product by the Parties and all budgets for such activities in the Field in the Territory.
Within ten (10) Business Days of the Effective Date, each of MAP and ALLERGAN shall designate an individual who shall initially serve as a co-chair for the JSC. The JSC shall have the authority to set up joint teams, committees and
subcommittees as necessary to Commercialize Product. 
 (b)     Responsibilities.  
The JSC shall have the following responsibilities: 
 (i)     Review and approve
Development Plans for the Initial Indication following submission of the initial New Drug Application for such Initial Indication, the Additional Required Indication and Additional Collaboration Indications in the Field in the Territory; 

(ii)     Review Regulatory Materials, including those materials for the Initial Indication, the
Additional Required Indication and Additional Collaboration Indications; 
 (iii)     Review
and agree on Manufacturing plans, including [***]; 

  
 15 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (iv)     Review and approve annual Commercialization
Plans for Product to Physician Targets in the Field in the Territory; 
 (v)     Establish a
process for the review and approval by the Parties of Promotional Materials for Product for Detailing to Physician Targets for use in the Field in the Territory; 

(vi)     Establish, review and approve budget for Shared Expenses in the Field in the Territory in
accordance with the terms of this Agreement; 
 (vii)     Establish, on an annual basis no
later than July 1, a two (2) year forecast, containing a projection of annual Product unit sales and associated annual PSMM Expenses reflecting Commercially Reasonable Efforts of the Parties in Commercializing Product (“Annual
Forecast And Budget”), which shall be in a format determined by the JSC or mutually agreed by the Parties; 
 (viii)     Approve recommendations and resolve disputes of the other committees and any subcommittees; and 

(ix)     Provide a forum for the Parties to exchange information and coordinate their respective
activities with respect to matters pertaining to Product for Physician Targets in the Field in the Territory. 

(c)     Decision-Making.   ALLERGAN and MAP will charter the JSC, PDC, JCC and any subcommittees
with the belief that vigorous interaction and cooperation between the Parties are necessary for the success of Product Development, Manufacturing and Commercialization to Physician Targets. The JSC may make decisions with respect to any subject
matter that is subject to the JSC’s decision-making authority and functions. The JSC shall operate by unanimous consent of its Members, with MAP’s JSC Member Designees having, collectively, one vote and ALLERGAN’s JSC Member Designees
having, collectively, one vote in all decisions. The JSC shall use Commercially Reasonable Efforts to make timely decisions and to resolve disputes. If the JSC is unable to resolve any dispute, controversy, or claim arising under this Agreement
within [***] after it first addresses such matter (or such longer period as the Parties may mutually agree), then such dispute, controversy or claim shall be referred to the Chief Executive Officer of MAP and a member of the ALLERGAN Executive
Committee (“Executives”). If a disagreement among Members of the JSC is still unresolved by the Executives [***] after referral to the Executives (or such longer period as the Parties may mutually agree), such disagreement shall be
resolved by MAP in its sole and final discretion; provided, however, that notwithstanding the foregoing, in the event the Members of the JSC cannot mutually agree on the budget for the initial Commercialization Plan pursuant to Section 6.2(c)
or any Annual Forecast And Budget, and such dispute cannot be resolved by the Executives, such dispute shall be resolved by [***]. 
 3.3     Alliance Managers. 

(a)     Each of the Parties shall appoint a single individual who possesses a general understanding of clinical,
regulatory, manufacturing and marketing issues to act as that 

  
 16 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Party’s point of contact for day to day communications between the Parties relating to the activities conducted under this Agreement (each, an “Alliance Manager”). Each
Party may change its designated Alliance Manager from time to time upon written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other
Party. 
 (b)     Each Alliance Manager shall strive to create and maintain a collaborative work environment
within and among the JSC, PDC, JCC and any subcommittees. Each Alliance Manager will also: (i) attempt to resolve, in the first instance, all matters of dispute arising in the JSC, PDC, JCC or any subcommittees; (ii) coordinate the
relevant functional representatives of the Parties in developing and executing strategies and Plans for Product to Physician Targets in the Field in the Territory; (iii) provide a single point of communication for seeking consensus both
internally within the respective Parties’ organizations and between the Parties regarding key strategy and Plan issues; (iv) identify and bring disputes to the attention of the JSC in a timely manner; (v) plan and coordinate
cooperative efforts and internal and external communications; (vi) track and report progress of the Parties against all Plans and activities; and (vii) ensure that governance activities, such as the conduct of required JSC, PDC, JCC and
any subcommittee meetings, take place, including by taking meeting minutes and producing such minutes as set forth in this Agreement, and by following up on relevant action items resulting from such meetings to confirm that such activities are
appropriately carried out or otherwise managed. 
 (c)     The Alliance Managers shall attend all
subcommittee meetings and JSC, PDC and JCC meetings and support the co-chairpersons of the JSC, PDC and JCC and subcommittees in the discharge of their responsibilities. Alliance Managers shall be nonvoting participants in the JSC, PDC, JCC and
subcommittee meetings, unless they are also appointed Members of the JSC, PDC, JCC or the subcommittee provided, however, that an Alliance Manager may bring any matter to the attention of the JSC or any subcommittee if such Alliance Manager
reasonably believes that such matter warrants such attention. 
 (d)     The Alliance Managers shall jointly
be responsible for working with the JSC and other committee Members to prepare and circulate an agenda in advance of each meeting of the JSC, PDC, JCC and subcommittee, and to prepare and issue initial drafts of minutes of each meeting within seven
(7) Business Days thereafter. Meeting minutes will not be finalized until both Parties’ representatives on the JSC, PDC, JCC or subcommittee review and confirm the accuracy of such minutes in writing, which such representatives shall do
and approve in writing within seven (7) Business Days of receiving such minutes for review and comment. 

3.4     Product Development Committee. 

(a)     Members; Officers.   The Parties will establish a Development committee for Product (the
“Product Development Committee” or “PDC”). Each PDC Member shall have expertise in pharmaceutical drug development, regulatory matters, clinical studies and/or other expertise to the extent relevant. Any PDC Member
Designee may designate a substitute Member Designee with due authority to temporarily attend and perform the functions of that 

  
 17 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Member Designee at any meeting of the PDC. The PDC shall be chaired by a representative of MAP. The secretary of the PDC shall be the MAP Alliance Manager. 

(b)     Responsibilities.   The PDC shall perform the following functions: 

(i)     Review and comment on the NDA for the Initial Indication; 

(ii)     Develop, review and recommend updates to Development Plans each year; 

(iii)     Oversee implementation of the Development Plans including managing the Development budget;

 (iv)     At least quarterly, review the Development budget; 

(v)     At each meeting of the PDC, review a comparison of actual Allowable Development Expenses and
Allowable Regulatory Expenses to budgeted expenses in the Development Plan budget for the Calendar Year-to-date, with such information covering a time period ending as closely as practicable to the date of the meeting; 

(vi)     Review and evaluate progress of the Development activities including CMC [***]; 

(vii)     Review the publication strategy in conjunction with the JCC; 

(viii)     Approve Clinical Trial protocols, budgets and designs; 

(ix)     Review and approve CRO’s and other Third Parties that will be utilized for Development
activities; 
 (x)     Coordinate the allocation of responsibilities among the Parties with
respect to Development of Product under the Development Plan; and 
 (xi)     Have such
other responsibilities as may be assigned to the PDC pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to time. 
 (c)     Decision-Making.   The PDC shall operate by unanimous consent of its Members, with MAP’s Member Designees having, collectively, one vote and
ALLERGAN’s Member Designees having, collectively, one vote in all decisions. The PDC shall use Commercially Reasonable Efforts to make timely decisions and to resolve disputes. If the PDC is unable to resolve any dispute, controversy, or claim
arising under this Agreement within a reasonable period after it first addresses such matter, then such dispute, controversy or claim shall be decided by the JSC. 

  
 18 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (d)     MAP agrees to provide periodic updates to the PDC regarding
MAP’s separate development activities for Follow-On Indications unless MAP is expressly prohibited by contract or Applicable Law. 
 3.5     Joint Commercialization Committee. 

(a)     Members; Officers.   The Parties shall establish a Commercialization committee for Product
(the “Joint Commercialization Committee” or “JCC”). Each JCC member shall have expertise in marketing and sales of pharmaceutical products. Any member of the JCC may designate a substitute with due authority to
temporarily attend and perform the functions of that member at any meeting of the JCC. The JCC shall be chaired by a representative of ALLERGAN. The secretary of the JCC shall be the ALLERGAN Alliance Manager. 

(b)     Responsibilities.   The JCC shall perform the following functions: 

(i)     Develop and subsequently review and make decisions relating to the Commercialization Plan
including a budget for PSMM Expenses; 
 (ii)     Oversee implementation of the
Commercialization Plan, throughout the Calendar Year, including managing the budget for PSMM Expenses; 

(iii)     Discuss the markets for Product in the Territory and opportunities and issues concerning
Commercialization of Product, including consideration of marketing and promotional strategy, marketing research plans, labelling, Product positioning and Product profile, including [***]; 

(iv)     Oversee and coordinate the sales efforts of the Parties; 

(v)     Review and make decisions regarding post-Initial Indication Approval Development activities,
taking into consideration the appropriateness of any Development activities including line extensions, Clinical Trials for purposes of new indications and Phase IV Clinical Trials in the context of the overall marketing and promotional strategy for
Product; 
 (vi)     Review and direct all indigent care use of Product; 

(vii)     Support the review of and approve Manufacturing, sales and prescription forecasts of
Product; 
 (viii)     Review data and reports arising from and generated in connection with
Commercialization of Product under the Commercialization Plan, market research studies, actual Product sales, Product prescription trends and Product sales forecasts; 

(ix)     At each meeting of the JCC, review a comparison of actual sales and marketing expenses to
the budgeted expenses in the relevant Commercialization 

  
 19 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Plan, with such information covering a time period ending as closely as practicable to the date of the meeting; 

(x)     Review and approve the general guidelines applicable to Product Commercialization to be
followed in the development of promotional materials and promotional activities to be used by the Parties in the co-promotion of Product; 
 (xi)     Lead the review and direct Product publication strategy, in consultation with the PDC; 

(xii)     Following review and approval by the Parties’ internal promotional materials review
committees, review and approve packaging and related materials, prior to any commercial use; and 

(xiii)     Have such other responsibilities as may be assigned to the JCC pursuant to this Agreement
or as may be mutually agreed upon by the Parties from time to time. 
 (c)    
Decision-Making.   The JCC shall operate by unanimous consent of its Members, with MAP’s Member Designees having, collectively, one vote and ALLERGAN’s Member Designees having, collectively, one vote in all decisions. The
JCC shall use Commercially Reasonable Efforts to make timely decisions and to resolve disputes. If the JCC is unable to resolve any dispute, controversy, or claim arising under this Agreement within a reasonable period after it first addresses such
matter, then such dispute, controversy or claim shall be decided by the JSC. 
 (d)     MAP agrees to
provide periodic updates to the JCC regarding MAP’s separate PCP marketing activities to the extent permitted and relevant to the Parties’ Product messaging activities under this Agreement. 

4.     DEVELOPMENT. 
 4.1    Development Responsibilities. 

(a)     Development Activities in the Territory.   MAP shall be responsible to Develop Product in
the Territory in the Field and shall be responsible for conducting Clinical Trials for Product in the Territory in the Field and conducting Chemistry, Manufacturing and Controls activities for Product. 

(b)     Additional Required Indication and Additional Collaboration Indications.   Subject to
Section 8.9 and the last sentence of this Section 4.1(b), the Parties agree to Develop Product for the Additional Required Indication and one (1) Additional Collaboration Indication in the Territory and will enter into suitable
Development Plans therefor by no later than [***] following the Effective Date. The Parties agree to cooperate in good faith to identify one (1) Additional Collaboration Indication in the Territory for which the costs and expenses
thereof shall be Allowable Development Expenses, subject to the provisions of Section 8.9 and the last sentence of this Section 4.1(b). The Parties may agree, at their sole discretion and

  
 20 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
without any obligation, to include other Follow-On Indications as Additional Collaboration Indications and the costs and expenses for such Additional Collaboration Indications shall be Allowable
Development Expenses. Commencing on the date of the First Commercial Sale, but not before, MAP may enroll patients in a Clinical Trial for Product for [***]. Unless the Parties otherwise agree, Development of Product for each Additional
Collaboration Indication shall be [***] such that enrollment of patients in a Clinical Trial for Product for [***], and enrollment of patients in a Clinical Trial for Product for any further Additional Collaboration Indications [***] for the [***].

 (c)     Follow-On Indications.     Following the date of the First Commercial
Sale, but not before, MAP shall be free to Develop Product for any Follow-On Indication(s) other than the Additional Required Indication and the Additional Collaboration Indications in the Territory at its sole cost and discretion; provided,
that MAP has presented such Follow-On Indication to ALLERGAN in writing to be considered as a potential Additional Collaboration Indication and ALLERGAN has confirmed in writing that such Follow-On Indication shall not be deemed an Additional
Collaboration Indication, provided further, that, [***]. Subject to Section 4.1(b), any sales of Product in the Territory resulting from prescriptions written by Physician Targets in Territory for any Follow-On Indications shall be
included in Net Sales. For clarity, nothing in this Agreement shall preclude MAP from developing Product for any Follow-On Indication for use outside the Territory. 
 4.2     Development Plans. 

(a)     Development Plans.   The Development of Product for the Additional Required Indication and
Additional Collaboration Indications and associated Allowable Development Expenses in the Field in the Territory shall be governed by this Agreement and by development plans (“Development Plans”). Development Plans together with
updates thereto made pursuant to Section 4.2(b) below, shall be created and executed by the PDC. Each Development Plan shall include, without limitation, details of all preclinical studies, toxicology, pharmacology studies, formulation, process
development, Clinical Trials, regulatory plans and other activities directed to obtaining Regulatory Approval of Product in the Field in the Territory and related timelines and budgets, as well as other activities necessary for Development of
Product in the Field in the Territory. 
 (b)     Updates.   The Parties shall, on an
annual basis, propose updates to the Development Plans for the following Calendar Year. Such updates may include Additional Collaboration Indications approved for Development in accordance with this Agreement. The Parties shall submit such updated
Development Plans to the JSC for review and comment by May 1 and for final approval by September 1 of each Calendar Year, which updated Development Plans shall apply to the following Calendar Year. The JSC shall provide comments on each
such updated Development Plan within [***] following its initial submission by the PDC and shall provide final approval of such updated Development Plan within [***] of its submission by the PDC for final approval. 

4.3     Subcontracting Permitted.   ALLERGAN acknowledges and agrees that portions of the work to be
performed by MAP under the Development Plans (including without 

  
 21 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
limitation Manufacture of Product) may be performed on behalf of MAP by Third Parties, provided that MAP shall be and remain responsible for the performance of its subcontractors. MAP shall keep
the PDC informed of its selection of potential subcontractors and shall give the PDC an opportunity to review any material contracts and material costs and expenses that will be Shared Expenses and that may be incurred through its engaging
subcontractors under this Agreement. 
 4.4     Clinical Data.   MAP will retain all right,
title, and interest in, to, and under all Clinical Trial data generated under the Agreement. 
 4.5    
Costs.   ALLERGAN shall reimburse MAP for fifty percent (50%) of Allowable Development Expenses incurred by MAP. Within 15 calendar days after the end of each Calendar Month, MAP shall invoice ALLERGAN for ALLERGAN’s portion
of Allowable Development Expenses in arrears on a Calendar Month basis. MAP’s invoice shall be in a form reasonably specified by ALLERGAN and include a detailed accounting of the Allowable Development Expenses incurred by MAP during the
relevant Calendar Month. Unless ALLERGAN disputes the invoiced amounts in accordance with the procedures set forth in Section 8.5, ALLERGAN shall remit payment to MAP of the full invoice amount within [***] of receipt thereof. 

4.6     Efforts.   The Parties shall use Commercially Reasonable Efforts consistent with their
responsibilities under this Agreement to Develop Product in the Field in the Territory in accordance with the Development Plan. 

5.     REGULATORY MATTERS. 

5.1     Preparation and Ownership of Regulatory Materials.   Subject to this Agreement, MAP shall
have sole right and principal responsibility for the preparation, submission and maintenance of Regulatory Materials and for seeking Regulatory Approval for Product in the Field in the Territory. MAP shall use Commercially Reasonable Efforts to
prepare, obtain, and maintain Regulatory Materials and seek Regulatory Approval for Product in the Field in the Territory and, to the extent required, Regulatory Approval of Promotional Materials. ALLERGAN shall have the opportunity to review the
draft label for the Initial Indication and all Follow-On Indications in the Territory and provide comments to MAP. MAP will consider, in good faith, ALLERGAN’s comments and recommendations with respect to such labeling. MAP shall own and retain
all right, title, and interest in, to, and under Regulatory Materials and Regulatory Approvals including all regulatory documentation with respect to Product. MAP shall solely own all Information arising in the course of Product Clinical Trials and
preclinical activities conducted pursuant to this Agreement. MAP shall be responsible for all interactions with Regulatory Authorities relating to Product. 
 5.2     Notice of Communication with Regulatory Authorities.   MAP shall be responsible for handling all complaints, recalls and communications with any Regulatory
Authority related to Product in the Field in the Territory and shall keep ALLERGAN promptly and fully informed as to the status of such activities. Each Party shall notify the other Party of any oral or written communications to or from Regulatory
Authorities on matters related to (a) Product in the Field in the Territory or which may reasonably be deemed to impact or 

  
 22 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
potentially impact Development, Manufacture, Commercialization or Regulatory Approval therefor, and (b) material regulatory or safety issues concerning Product in any jurisdiction which may
reasonably be deemed to adversely impact or potentially adversely impact Product (or sales thereof) in the Field in the Territory, and in each case in (a) and (b) above such Party shall provide the other Party with copies of any such
written communications within three (3) Business Days of receipt or delivery of such communication, as the case may be, or such earlier date as required by Applicable Laws, the FDA or other relevant Regulatory Authority. Without limiting the
foregoing, MAP shall promptly notify ALLERGAN of any assessment or inspection of MAP by any Regulatory Authority regarding MAP’s compliance with cGMP and shall promptly provide to ALLERGAN information relating to the outcome of such assessment
or inspection. In addition to the foregoing, MAP shall permit ALLERGAN to review and comment on the NDA for the Initial Indication for Product and all regulatory applications for Follow-On Indications in the Field in the Territory and give ALLERGAN
reasonable opportunity to review and comment on any proposed response to any such oral or written communications to or from any Regulatory Authority prior to submitting any response thereto, and provide ALLERGAN with a copy of the final response as
specified herein. ALLERGAN shall provide all such comments promptly after receiving the relevant information. MAP will consider, in good faith, ALLERGAN’s comments and recommendations with respect to such regulatory materials. MAP shall provide
reasonable advance notice to ALLERGAN with respect to, and permit [***] ALLERGAN representatives (as reasonably requested by ALLERGAN), or such other number of attendees as the Parties may agree, [***] all meetings (including substantive telephonic
meetings) with the FDA in connection with Product in the Field in the Territory, as well as participate in any MAP strategic planning meetings in preparation for such FDA meetings. Unless otherwise agreed to by the Parties, ALLERGAN shall not,
without prior consultation with, and agreement of, MAP, or unless so required by Applicable Laws, correspond or communicate with any Regulatory Authority concerning Product or any Regulatory Material related thereto. 

5.3     Pharmacovigilance and Safety Monitoring Activities.   MAP shall be primarily responsible for
monitoring all Clinical Trials for Product; maintaining adverse event, complaint and safety databases; and filing all required reports to Regulatory Authorities related to Product. Within [***] after the Effective Date, Safety Data Exchange
Agreements (“SDEA”) will be implemented between the Parties governing the Parties’ respective responsibilities with respect to adverse events, complaints and other safety-related matters with respect to Product. Specific details
regarding the exchange and management of information relating to adverse events related to the use of Product shall be delineated in a SDEA, which shall, among other terms, specify that: MAP shall be responsible for adverse event and Product
complaint reporting to a Regulatory Authority; ALLERGAN shall maintain a record noting in reasonable detail any and all complaints and notices of adverse events it receives with respect to Product; and ALLERGAN shall provide to MAP or its designee
all such information to the contacts specified by MAP in a format and in a form reasonably specified by MAP so as to enable MAP to comply with Applicable Laws (with such information being provided, in any event within two (2) Business Days
after such adverse event or complaint is first received by ALLERGAN if the adverse event or complaint concerns a matter with the potential to adversely affect patient safety, and within seven (7) Business Days after such receipt otherwise). The
SDEA will specify that MAP shall promptly provide to ALLERGAN copies of any reports that it files with a Regulatory 

  
 23 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Authority describing adverse events or complaints relating to Product within three (3) Business Days after delivery to a Regulatory Authority. 

5.4     Risk Evaluation and Mitigation Strategies (“REMS”).   MAP shall be primarily
responsible for executing any REMS program related to Product required by a Regulatory Authority in the Territory. Through the JSC and the JCC, the Parties will jointly discuss, prepare and implement any REMS Program required by Regulatory
Authorities in the Territory. 
 5.5     Costs.   ALLERGAN shall reimburse MAP for fifty
percent (50%) of Allowable Regulatory Expenses incurred by MAP. Within 15 calendar days after the end of each Calendar Month, MAP shall invoice ALLERGAN for ALLERGAN’s portion of Allowable Regulatory Expenses in arrears on a Calendar Month
basis. MAP’s invoice shall be in a form reasonably specified by ALLERGAN and include a detailed accounting of the Allowable Regulatory Expenses incurred by MAP during the relevant Calendar Month. Unless ALLERGAN disputes the invoiced amounts,
ALLERGAN shall remit payment to MAP of the full invoice amount within [***] of receipt thereof. Notwithstanding anything contained herein, in the event that [***] pursuant to which [***], beginning on the effective date of such [***], ALLERGAN shall
[***]. If no such [***], the Parties agree to [***] is appropriate. 
 5.6     Product Recall.

 (a)     Notification and Recall.   In the event that any government agency or Regulatory
Authority issues or requests a recall or takes similar action in connection with Product in the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or
market withdrawal in the Territory, the Party notified of or desiring such recall or market withdrawal shall promptly advise the other Party thereof by facsimile or email. Following notification of a recall, the JSC shall decide and have control of
whether to conduct a recall or market withdrawal (except in the case of a government-mandated recall) in the Territory and the manner in which any such recall or market withdrawal shall be conducted. 

(b)     Recall Costs and Expenses.   MAP shall be solely responsible for the costs and expenses of
any recall of Product, provided, however, that ALLERGAN shall bear the portion of any costs and expenses of a recall to the extent that such costs and expenses directly resulted from ALLERGAN’s gross negligence, willful misconduct or
intentional omission, or the material breach of ALLERGAN’s representations, warranties, covenants or other obligations as set forth in or arising out of this Agreement. Such costs and expenses of recall shall include costs and expenses for
notification, withdrawal, return and destruction of recalled Product and any refunds of amounts paid for recalled Product. 

6.     COMMERCIALIZATION. 

6.1     Commercialization.   The Parties shall be jointly responsible for the Commercialization of
Product to Physician Targets in the Territory in the Field in accordance with the terms of this Agreement, the Co-Promotion Agreement and the Commercialization Plan(s) developed pursuant to this Agreement and the Co-Promotion Agreement. 

  
 24 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 6.2     Commercialization Plans. 

(a)     The strategy for the Commercialization of Product to Physician Targets in the Field in the Territory during
the term of this Agreement shall be described in one or more comprehensive plans that describe the pre-launch, launch and subsequent Commercialization activities (including estimated Shared Expenses, advertising, education, planning, marketing,
sales force training and allocation) (each, a “Commercialization Plan”). 
 (b)    
Attached hereto as Exhibit 6.2(b) is a forecast of the prescriptions for Product in the in the Field in the Territory during each of the [***] following First Commercial Sale (the “Signing Date TRx Forecast”). 

(c)     No later than ninety (90) days following the Effective Date, the JCC shall have agreed upon and
presented to the JSC an initial Commercialization Plan setting forth the pre-launch and launch year Commercialization activities and a preliminary Net Sales forecast and budget for Product in the in the Field in the Territory during the Product
Launch Period. The amounts set forth in such Commercialization Plan (including without limitation, Net Sales forecast and budget, and other costs and expenses) will be based upon the prescription forecasts in the Signing Date TRx Forecast, and the
prescription forecasts in such Commercialization Plan shall not vary from the Signing Date TRx Forecast without the mutual written consent of both MAP and ALLERGAN. 
 (d)     Thereafter, on or before May 1 of each Calendar Year during the term of this Agreement, the JCC shall present to the JSC for its approval an updated Commercialization Plan
including a budget for Shared Expenses in accordance with the then-current Annual Forecast And Budget for Product in the Field in the Territory for the next two (2) Calendar Years. On or before September 1 of such Calendar Year, the JSC
shall have approved such Commercialization Plan, including the Annual Forecast And Budget contained therein. Notwithstanding anything contained herein, without the mutual written consent of both Parties, neither Party shall have the right to bill
the other Party or include in Shared Expenses any direct or indirect Commercialization expenses other than those expressly provided for in the Annual Forecast and Budget, unless agreed to by the other Party. 

(e)     All Commercialization Plans developed in accordance with this Agreement shall generally conform to the level
of detail utilized by ALLERGAN in preparation of its own product commercialization plans, with the overall objective of maximizing the economic value of Product in the Field in the Territory. Without limiting the foregoing, all Commercialization
Plans shall include but not be limited to: (i) details regarding demographics, market dynamics, and market strategies for Product and patient population, estimated launch dates, and sales and expense forecasts; (ii) a marketing plan
(including plans related to the prelaunch, launch, promotion, reimbursement and sales of Product, which shall include pricing strategy, sampling plans, public relations and promotional communications and a reasonably descriptive overview of the
marketing and advertising campaigns proposed to be conducted; (iii) health economics and/or quality of life studies to be performed or other payor related activities required to determine placement of product with payors, and other payor
related studies to establish prices for Product; (iv) sales force forecasts and allocation, physician training and 

  
 25 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
education, detail frequency, Physician Target Detail plans and allocations of percentages of Details and identities of Physician Targets to be provided or contacted by the Parties, and sales
incentive compensation programs for Commercialization of Product to Physician Targets in the Field in the Territory; and (v) Phase IV Clinical Trial activities. Each Commercialization Plan shall include an associated budget for
Commercialization of Product, including without limitation the Third Parties to be utilized in such activities and the arrangements with them that have been or are proposed to be agreed upon and a budget of the costs and expenses expected to be
incurred in connection with performing the Commercialization Plan. 
 6.3     Sales Force Efforts.

 (a)     Additional requirements regarding the overall Commercialization efforts that each of the Parties
shall provide in support of Product Commercialization to Physician Targets in the Field in the Territory shall be set forth in the Co-Promotion Agreement and the applicable Commercialization Plan. In accordance with the Co-Promotion Agreement, sales
force costs and expenses will be calculated on a PDE Costs basis. 
 (b)     Subject to the minimum Sales
Force requirements set forth herein and in the Co-Promotion Agreement, each Party shall build and deploy a Sales Force that can adequately deliver the specified number of PDEs as set forth in the then-current Commercialization Plan. Notwithstanding
the foregoing, at all times during the [***] period immediately following the First Commercial Sale, unless otherwise expressly agreed by the Parties in writing: 

(i)     ALLERGAN shall deliver a minimum of [***] PDEs per Calendar Quarter to Physician Targets; and

 (ii)     MAP shall deliver a minimum of [***] PDEs per Calendar Quarter to Physician
Targets. 
 (c)     Unless otherwise specified in the then-applicable Commercialization Plan: 

(i)     all Details of Product in the Field in the Territory performed by MAP during the [***] period
immediately following the First Commercial Sale shall be Primary Details; and 
 (ii)    
all Details of Product in the Field in the Territory performed by ALLERGAN shall be Secondary Details; provided, that ALLERGAN, at its sole discretion, may elect to perform Primary Details of Product but, in such event, would only be entitled to PDE
credit for a Secondary Detail. 
 (d)     The Parties will cooperate with each other in developing
strategies for the Parties’ Sales Forces to effectively target the [***] of migraine medication prescribers and other Physician Targets who are determined by MAP or ALLERGAN to be appropriate targets for Product Details. 

  
 26 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 6.4     PDE Expense Cap.   Notwithstanding anything in
this Agreement to the contrary, ALLERGAN’s aggregate PDE Costs included in Shared Expenses shall not exceed [***] in any Calendar Quarter and MAP’s aggregate PDE Costs included in Shared Expenses shall not exceed [***] in any Calendar
Quarter, with such dollar amounts subject to adjustment for inflation based upon the then-current PDE Rate. 

6.5     MAP Sales Force. 
 (a)     No later than [***] prior to the PDUFA Date, MAP shall have recruited and hired as employees of MAP, its first and second level sales management team for the Commercialization
of Product to Physician Targets in the Field in the Territory (the “Sales Force Management Team”). 

(b)     In addition, MAP shall establish a sales force comprised of [***] FTEs, trained and placed sales
representatives to Detail Product to Physician Targets in the Field in the Territory (the “MAP Sales Force”) with any increase or decrease in the number of such sales representatives being subject to the recommendation of the JCC
and the approval of the JSC in accordance with the terms of the this Agreement. The MAP Sales Force shall be deployed in the Territory in accordance with the terms of this Agreement and the Co-Promotion Agreement upon the date of First Commercial
Sale. The Sales Force Management Team shall work in good faith in accordance with the requirements of this Agreement and the Co-Promotion Agreement to recruit the MAP Sales Force, such that the majority of MAP Sales Force members have been extended
contingent hire offers not later than [***]. 
 (c)     In addition to compliance with the requirements set
forth herein, the Sales Force Management Team and the MAP Sales Force shall at all times comply with the requirements set forth in, and shall be recruited, employed, trained and otherwise developed in accordance with terms of, the Co-Promotion
Agreement. 
 6.6     Packaging; Promotional Materials.   MAP shall own and be responsible
for all final packaging (non-commercial and commercial) and Promotional Materials for use in Commercializing Product. The JSC shall be responsible for establishing a process for the Parties to review and approve Promotional Materials for
Commercialization of Product to Physician Targets for use in the Field in the Territory, materials that will be distributed by medical science liaisons for Product in the Field in the Territory, and comparable materials. 

6.7     Costs.   Shared Expenses shall be treated in accordance with the provisions of
Section 8.3 of this Agreement, the Co-Promotion Agreement and the relevant Commercialization Plan. Except as otherwise expressly set forth herein, each Party shall be solely responsible for any of their respective costs and expenses associated
with Commercialization of Product that are not Shared Expenses. For the avoidance of doubt, (a) costs and expenses for MAP’s Sales Force Management Team and ALLERGAN’s Sales Force Management Team shall be borne solely by each
respective Party and shall not be Shared Expenses, and (b) costs and expenses for the MAP Sales Force and the ALLERGAN Sales Force shall be included in Shared Expenses solely by means of the calculation of PDE Costs. 

  
 27 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 6.8     Efforts.   Subject to the provisions of this
Agreement and the Co-Promotion Agreement, as promptly as reasonably practicable after obtaining Initial Indication Approval (and in any event within [***] after Initial Indication Approval), the Parties shall use Commercially Reasonable Efforts to
launch Product to Physician Targets in the Field in the Territory and shall thereafter continue to use Commercially Reasonable Efforts to Commercialize Product to Physician Targets in the Field in the Territory in accordance with the terms of this
Agreement and the Co-Promotion Agreement and the applicable Commercialization Plan. Without limiting the foregoing, the Parties shall use Commercially Reasonable Efforts to Detail Product to all Physician Targets that are within [***] of migraine
medication prescribers. 
 6.9     Commercialization of Other Products.   Notwithstanding
anything contained herein, neither Party shall be precluded from Commercializing its products, other than Product, to Physician Targets in the Territory, or preclude MAP (or its Affiliates or Sublicensees) from Commercializing Product to Physicians
who are not Physician Targets. 
 7.     MANUFACTURING AND
DISTRIBUTION. 
 7.1     General.   MAP shall Manufacture and distribute
Product for clinical and commercial use pursuant to this Agreement. Such Product shall comply with applicable Product Specifications and shall be Manufactured in accordance with such specifications and Applicable Laws. MAP shall use Commercially
Reasonable Efforts to establish a fully validated and approved supply process for Manufacture of commercial supplies of Product meeting Product Specifications that have been Manufactured in compliance with the applicable Product Specifications and
Applicable Laws, including without limitation cGMP, and shall engage in such scale-up, second source supply and Manufacturing automation activities as the Parties may mutually agree. [***]. 

7.2     Costs.   Except as otherwise set forth herein, all costs and expenses incurred in the
course of Manufacturing activities shall be included in Shared Expenses as set forth in Section 8.3. Notwithstanding anything to the contrary in this Agreement, unless otherwise agreed to by the Parties in writing, in no event shall ALLERGAN be
responsible (or obligated to pay or reimburse) for any Manufacturing Expenses (as defined below) incurred by MAP prior to Initial Indication Approval except that ALLERGAN shall reimburse MAP for fifty percent (50%) of Allowable Pre-Approval
Manufacturing Expenses incurred by MAP. Within fifteen (15) calendar days after the end of each Calendar Month, MAP shall invoice ALLERGAN for ALLERGAN’s portion of Allowable Pre-Approval Manufacturing Expenses in arrears on a Calendar
Month basis. MAP’s invoice shall be in a form reasonably specified by ALLERGAN and include a detailed accounting of the Allowable Pre-Approval Manufacturing Expenses incurred by MAP during the relevant Calendar Month. Unless ALLERGAN disputes
the invoiced amounts in accordance with the procedures set forth in Section 8.5, ALLERGAN shall remit payment to MAP of the full invoice amount within [***] of receipt thereof. “Manufacturing Expenses” shall mean Cost of Goods
Sold (as defined in Exhibit 1.113), excluding any Manufacturing Improvement Expenses. 

  
 28 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8.     PAYMENT
OBLIGATIONS. 
 8.1     Upfront Payment.   In
consideration for the rights granted to ALLERGAN under this Agreement and in recognition for prior investment in development of Product, ALLERGAN shall pay to MAP a one-time-only, nonrefundable, noncreditable payment of Sixty Million Dollars
($60,000,000) within seven (7) Business Days after the Effective Date. 
 8.2     Milestone
Payments. 
 (a)     Milestones for Pre-Commercialization.   In consideration for the
rights granted to ALLERGAN under this Agreement and in recognition for prior investment in development of Product, ALLERGAN shall make the following nonrefundable, noncreditable (except as set forth in Section 8.2(c)) milestone payments to MAP
with respect to Product, within thirty (30) days from the date of invoice by MAP after achievement of the relevant milestone for Product as set forth in the table below. The milestones in this Section 8.2 are cumulative, such that under no
circumstances is any single milestone payment to be deemed in lieu of, or to be substituted for, another milestone payment. 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 Acceptance for filing of an NDA for Product for the Initial Indication
	  	 	$20,000,000	  
		
	 First Commercial Sale of Product for the Initial Indication
	  	 	$50,000,000	  
		
	If ALLERGAN exercises its option under Section 2.4, the first Regulatory Approval of an New Drug Submission or equivalent by Health Canada for Product for the Initial
Indication	  	 	$2,000,000	  
		
	 Achievement of FDA-approved Product labeling in the United States that [***]
	  	 	$15,000,000	  
		
	 Achievement of FDA-approved Product labeling in the United States [***]
	  	 	$10,000,000	  

(b)     For clarity, each milestone under Section 8.2(a) will be paid only once, the total equaling a maximum of
Ninety-Seven Million Dollars ($97,000,000). 
 (c)     Any costs and expenses attributable to ALLERGAN and
included as part of Allowable Development Expenses or Allowable Regulatory Expenses that are directly related to achieving the FDA-Approved Product labelling milestones set forth above shall be credited against the amount due when such milestone is
achieved. 
 8.3     Sharing of Distributable Profit and Loss. 

  
 29 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a)     MAP shall distribute Product and book Net Sales for Product in
the Territory. 
 (b)     For the period beginning on the date of the First Commercial Sale and expiring on
the earlier of: (x) the date on which MAP PCP Detail is triggered; and (y) [***] (such period, the “PCP Net Sales Period”), Product sales resulting from prescriptions written by PCPs (“PCP Net Sales”)
shall be included in Net Sales and in the calculation of Distributable Profit and Distributable Loss under this Agreement, after which time such sales shall not be included in Net Sales and in the calculation of Distributable Profit and
Distributable Loss under this Agreement. 
 (c)     Commencing on the Effective Date, the Parties shall
share Distributable Profit and Distributable Loss equally such that each Party receives fifty percent (50%) of the Distributable Profit and bears fifty percent (50%) of the Distributable Loss. 

8.4     Accounting and Reporting of Net Sales and Shared Expenses. 

(a)     Within [***] after the end of each Calendar Quarter, MAP shall submit to ALLERGAN an estimate report
providing in reasonable detail all Shared Expenses incurred by MAP (the “MAP Estimated Shared Expenses” and such report the “MAP Shared Expenses Estimate Report”), including a calculation showing as separate line
items each component of Shared Expenses. Within [***] after the end of each Calendar Quarter, ALLERGAN shall submit to MAP an estimate report providing in reasonable detail all Shared Expenses incurred by ALLERGAN (the “ALLERGAN Estimated
Shared Expenses” and such report “ALLERGAN Shared Expenses Estimate Report”), including a calculation showing as separate line items each component of Shared Expenses. Each such estimate report shall be considered
Confidential Information of the submitting Party, subject to the terms and conditions of Article 15 herein. If within [***] of receipt by a Party of the reports described in this Section 8.4(a), such Party informs the other Party that it
disputes the amount of all or a portion of any Shared Expense, the Parties shall meet promptly and attempt in good faith to resolve such dispute. 
 (b)     MAP agrees to determine Net Sales in the Field in the Territory using its standard accounting procedures, consistently applied and consistent with this Agreement and with GAAP,
as if Product was a solely owned product of MAP. In the case of amounts to be calculated by or using information from Third Parties (for example, Net Sales by Sublicensees), such amounts shall be determined in accordance with GAAP in effect in the
country in which such Third Party is established. 
 (c)     In the event of the payment or receipt of
non-cash consideration in connection with the performance of activities under this Agreement, MAP shall advise the JSC of such transaction, including without limitation MAP’s assessment of the fair market value of such non-cash consideration
and the basis therefor. Such transaction shall be accounted for on a cash equivalent basis. 
 8.5    
Process, Reports and Financial Reconciliation. 

  
 30 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a)     Within [***] after the end of each calendar month, MAP shall
submit to ALLERGAN (i) an estimate report providing in reasonable detail an accounting of the amount invoiced by MAP or its Affiliates for all sales of Product in the Territory to unaffiliated Third Parties during such calendar month, and
(ii) an estimate report providing in reasonable detail an accounting of all Net Sales, if any, derived from prescriptions written by Physician Targets in the Territory during such calendar month, including the total gross sales and the
allowable deductions therefrom. 
 (b)     Within [***] after the end of each Calendar Quarter (the
“Recently Ended Quarter”), MAP shall submit to ALLERGAN an estimate report providing in reasonable detail an accounting of all Net Sales, including the total gross sales and the allowable deductions therefrom (the “Net Sales
Estimate Report”). Attached hereto as Exhibit 8.5 is a detailed example of calculation of Net Sales in accordance with this Agreement. Using the Net Sales Estimate Report, the MAP Shared Expenses Estimate Report and the ALLERGAN Shared
Expenses Estimate Report, MAP shall, within [***] after the end of the Recently Ended Quarter, prepare a report of the Distributable Loss or Distributable Profit for the Recently Ended Quarter (the “Distributable Loss Report” or
“Distributable Profit Report”). The Distributable Loss Report or Distributable Profit Report shall also include a true and accurate reconciliation, if any, of Distributable Loss or Distributable Profit for the Calendar Quarter
immediately preceding the Recently Ended Quarter (the “Prior Quarter”), as follows: 

(i)     a statement of finalized Net Sales for the Recently Ended Quarter and the Prior Quarter;

 (ii)     a statement of the finalized MAP Shared Expenses, the ALLERGAN Shared Expenses
and the total Shared Expenses for the Recently Ended Quarter; 
 (iii)     a calculation of
estimated Distributable Loss or Distributable Profit for the Recently Ended Quarter including any adjustment to the Prior Quarter’s estimated Distributable Profit or Distributable Loss, which adjustment shall be applied in the payment due in
the Recently Ended Quarter, as applicable, such that each Party shall share equally in the Distributable Profit or Distributable Loss as set forth in Section 8.3; and 

(iv)     a statement of any amount owed by one Party to the other Party (“Net
Payment”), to be determined as follows and as further illustrated in Exhibit 8.3: 
 A.
    If the Distributable Profit is greater than zero (0), MAP shall pay to ALLERGAN an amount equal to Shared Expenses incurred by ALLERGAN plus fifty percent (50%) of the Distributable Profit. 

B.     If the Distributable Profit is equal to zero, MAP shall pay to ALLERGAN an amount equal to
the Shared Expenses incurred by ALLERGAN. 
 C.     If there is Distributable Loss, and:

  
 31 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (1)     If there is a MAP Operating Loss and such MAP
Operating Loss is greater than the Shared Expenses incurred by ALLERGAN, then ALLERGAN shall pay to MAP an amount equal to the difference between 50% of the Distributable Loss and the Shared Expenses incurred by ALLERGAN; 

(2)     If there is a MAP Operating Loss and such MAP Operating Loss is less than the Shared
Expenses incurred by ALLERGAN, then MAP shall pay to ALLERGAN an amount equal to the difference between 50% of the Distributable Loss and the Shared Expenses incurred by ALLERGAN; or 

(3)     If there is a MAP Operating Profit, then MAP shall pay to ALLERGAN an amount equal to the
difference between 50% of the Distributable Loss and the Shared Expenses incurred by ALLERGAN. 
 Within [***] after MAP provides ALLERGAN the
reports set forth in this Section 8.5 (other than reports delivered pursuant to Section 8.5(a)), ALLERGAN or MAP, as the case may be, shall pay the Net Payment to the other Party. If within [***] of receipt by ALLERGAN of the Distributable
Loss Report or the Distributable Profit Report, ALLERGAN informs MAP that it disputes the amount of all or a portion of any payment due, the Parties shall meet promptly and attempt in good faith to resolve such dispute. To the extent the dispute is
not resolved, such matter shall be presented to the JSC for resolution. 
 (c)    If during the term of this
Agreement, either Party is required, as a company that reports it financial results to the U.S. Securities and Exchange Commission (“SEC”) in accordance with GAAP, to include certain financial results of the other Party in such
Party’s consolidated financial statements, such Party shall timely provide to the other Party its financial statements reasonably requested by such Party, which may include quarterly (unaudited) and yearly (audited) income statements, balance
sheets, and statements of cash flows (the “Financial Statements”) and related supplemental information required for appropriate GAAP footnote disclosures by the requesting Party. All Financial Statements and related supplemental
information shall be prepared in accordance with GAAP. Any information provided by a Party to the other Party under this section will be treated as such disclosing Party’s Confidential Information, unless required by GAAP to be disclosed as
part of a Party’s Financial Statements filed with the SEC. 
 8.6     Currency of
Payment.   All payments to be made under this Agreement shall be made in Dollars. Net Sales made in foreign currencies shall be converted into Dollars in accordance with GAAP using the exchange rates set forth in The Wall Street
Journal (Eastern United States Edition) for each of the three (3) calendar months included in the Calendar Quarter in which such Net Sales were made. Any cost items incurred by ALLERGAN in non-Dollar currencies will be converted into Dollars
using the exchange rate ALLERGAN uses in preparing its financial statements pursuant to GAAP for the applicable reporting period. All such converted Net Sales and cost items shall be consolidated with U.S. Net Sales for each Calendar Quarter and the
applicable payments determined therefrom. 

  
 32 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8.7     Withholding.   In the event that any payment
under this Agreement becomes subject to withholding taxes, other than income tax, under Applicable Laws, the payor may withhold from the payment the amount of such taxes due. Payor will timely pay to the proper governmental authority the amount
of any taxes withheld and will provide the payee with an official tax certificate or other evidence of tax obligation together with proof of payment from the relevant governmental authority sufficient to enable payee to claim such payment of
taxes. The Parties agree to cooperate with one another and use reasonable efforts to minimize or eliminate such withholding taxes when possible. 
 8.8     Initial Indication Costs and Expenses Prior to First Commercial Sale.   Notwithstanding anything to the contrary in this Agreement and except for Allowable
Pre-Approval Manufacturing Expenses as specifically set forth in Section 7.2 and except as specifically set forth in the proviso in this Section 8.8, unless otherwise agreed to by ALLERGAN in writing, in no event shall ALLERGAN be
responsible (or obligated to pay or reimburse) for any Development, CMC, or other non Commercialization costs or expenses incurred or accrued by MAP prior to the date of First Commercial Sale, and such costs and expenses shall not be considered
Shared Expenses, Allowable Development Expenses, Allowable Patent Expenses or Allowable Regulatory Expenses; provided, however, that if after the Effective Date and prior to the date of the Initial Indication Approval, MAP receives notification from
the FDA that Initial Indication Approval will not be obtained without incurring additional Development, Manufacturing and CMC expenses, and MAP incurs such costs and expenses in [***]. 

8.9     Additional Required Indication and Additional Collaboration Indication Development Cost and Expense
Cap.   Notwithstanding anything to the contrary in this Agreement, unless otherwise agreed to by the Parties in writing and other than costs and expenses related to REMS and patient registries, in no event shall either Party be
responsible (or obligated to pay or reimburse) [***], for any Development, CMC, Manufacturing, or non-Commercialization costs or expenses incurred or accrued by MAP for the Development of the Additional Required Indication and any other Additional
Collaboration Indications. 
 9.     RECORD RETENTION AND
AUDITS. 
 9.1     Record Retention.   MAP shall keep
complete and accurate records pertaining to Net Sales of and Shared Expenses for Product in sufficient detail to permit ALLERGAN to verify the costs and expenses related to the efforts of MAP under this Agreement for which ALLERGAN is responsible
for payment or reimbursement. ALLERGAN shall keep complete and accurate records of Shared Expenses incurred by ALLERGAN for Product, in sufficient detail to permit MAP to verify the costs related to the efforts of ALLERGAN under this Agreement. The
records to be maintained by each Party under this Section shall be maintained for a minimum of [***] following the Calendar Year in which the corresponding efforts or payments, as the case may be, were made under this Agreement or longer if in
accordance with Applicable Laws. 
 9.2     Audit Request.   Each of the Parties shall, at
its cost and expense (except as provided below), have the right to audit, not more than [***] during each Calendar Year and 

  
 33 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
during regular business hours upon reasonable prior written notice which shall in no event be less than [***], the records maintained by the other Party under Section 9.1, to determine with
respect to any Calendar Year the accuracy of any report or payment made under this Agreement in the [***]. Neither Party may re-audit the other Party’s records once audited. If a Party desires to audit such records, it shall engage an
independent, certified public accountant reasonably acceptable to the other Party, to examine such records under obligations of confidentiality no less protective as those set forth in Article 15. Such accountant shall be instructed to provide to
the auditing Party a report verifying any report made or payment submitted by the audited Party during such period, but shall not disclose to the auditing Party any Confidential Information of the audited Party not necessary therefor. The cost and
expense of such audit shall be borne by the auditing Party provided that in the event an error resulting in underpayment by the audited Party or overpayment by the auditing Party of more than [***] is discovered, then such auditing expenses shall be
paid by the audited Party. If an audit report prepared under this Section 9.2 concludes that additional payment amounts were owed to a Party during any period, the debtor Party shall pay such payment amount, plus interest thereon at a rate of
[***] compounding annually from the date such amounts were payable, within [***] of the date the creditor Party delivers to the debtor Party such written audit report so concluding, unless the debtor Party notifies the creditor Party of any dispute
regarding the audit report and commences proceedings under Section 18.12 within [***] of delivery of the audit report (in which case the payment shall be delayed until conclusion of the proceeding). No auditors engaged in any audits under this
Section 9.2 shall be paid on a contingency basis. Any Information received by an auditing Party pursuant to this Section 9.2 shall be deemed to be Confidential Information of the audited Party. 

10.     INVENTIONS, KNOW-HOW AND
PATENTS. 
  10.1     Existing Intellectual
Property.   OTHER THAN AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY GRANTS ANY RIGHT, TITLE, OR INTEREST IN ANY PATENT, PATENT APPLICATION, INFORMATION, OR OTHER INTELLECTUAL PROPERTY RIGHT CONTROLLED BY SUCH PARTY TO THE
OTHER PARTY. 
  10.2     Ownership of Inventions.   MAP shall solely own all
Inventions [***] and/or [***] that are related to [***] by (i) [***] or (ii) [***], which Invention is [***] (an “ALLERGAN Inventor”) (“MAP Inventions”). In the case of an ALLERGAN Inventor, ALLERGAN shall
promptly notify MAP in writing, providing reasonable detail, of such MAP Invention. Without additional consideration, ALLERGAN hereby assigns to MAP any and all of its right, title and interest in and to any such MAP Inventions (including without
limitation all Patents or Patent Applications claiming such MAP Inventions), and shall reasonably cooperate with and take reasonable additional actions and execute such agreements, instruments, and documents as may be reasonably required to perfect
MAP’s right, title and interest in, to, and under such MAP Inventions; provided, however, that MAP hereby covenants and agrees that it shall not assert such MAP Invention against ALLERGAN (including its Affiliates, successors, assigns,
licensees, distributors, contractors, agents, and customers). ALLERGAN shall include provisions in its relevant agreements relating to this Agreement requiring its Sublicensees, Affiliates, independent contractors, employees and agents to
(i) so assign to ALLERGAN any and all of their respective right, title and interest in, to, and under the foregoing as necessary for 

  
 34 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
ALLERGAN to comply with its assignment obligation as set forth in this Section 10.2; and (ii) cooperate with and take reasonable additional actions and execute such agreements,
instruments, and documents as may be reasonably required to perfect right, title and interest in, to, and under such MAP Inventions. Ownership of any and all Inventions other than MAP Inventions shall be based on inventorship as determined in
accordance with U.S. Patent law; provided, however, in the case of [***] made during the term of this Agreement that is [***], ALLERGAN [***]. For the avoidance of doubt, if the [***] during the Term of this Agreement, such [***] for purposes of the
preceding sentence. The Parties expressly agree and intend that the [***] set forth in this Section 10.2 shall [***]. 

10.3    Patent Prosecution and Maintenance.   MAP shall prosecute and maintain all Patents and
Patent Applications in the Territory included in MAP Patent Rights in full compliance with all applicable laws, regulations, and duties. MAP shall keep ALLERGAN timely apprised of all significant events concerning such prosecution and maintenance in
the Territory, or that may impact such Patents and Patent Applications in the Territory (including, without limitation, office actions, responses to office actions, requests for re-examination, interference proceedings, term adjustments, requests
for term extensions, and abandonment or discontinuation decisions), and shall reasonably consider, in good faith, all ALLERGAN input regarding such prosecution and maintenance in the Territory. In the event that MAP elects not to prosecute and/or
maintain Product Specific Patent Rights in the Territory, it shall promptly notify ALLERGAN of such election not to prosecute and Maintain such Product Specific Patent Rights, and ALLERGAN shall have the right, but not the obligation, to elect,
within [***] of written notification of MAP’s intent not to prosecute and/or maintain such Product Specific Patent Rights, to perform such activities and [***] the costs and expenses associated with such prosecution [***]. For purposes of this
Section 10, [***] shall only include the [***], including up to [***], recorded as an expense in accordance with GAAP, and statutory fees. 
 10.4    Patent Costs. 

(a)       MAP Allowable Patent Expenses.   ALLERGAN shall reimburse MAP for fifty percent
(50%) of the Allowable Patent Expenses incurred by MAP. Within fifteen (15) calendar days after the end of each Calendar Month, MAP shall invoice ALLERGAN for ALLERGAN’s portion of the Allowable Patent Expenses in arrears on a
Calendar Month basis. MAP’s invoice shall be in a form reasonably specified by ALLERGAN and include a detailed accounting of the Allowable Patent Expenses incurred by MAP during the relevant Calendar Month. Unless ALLERGAN disputes the invoiced
amounts, ALLERGAN shall remit payment to MAP of the full invoice amount within [***] of receipt thereof. Notwithstanding anything contained herein, in the event that [***] pursuant to which [***], beginning on the effective date of such [***]. If no
such [***] and if the [***], the Parties agree to [***] is appropriate. 
 (b)       ALLERGAN
Patent Expenses.   MAP shall reimburse ALLERGAN for [***] of ALLERGAN Patent Expenses. Within 15 calendar days after the end of each Calendar Quarter, ALLERGAN shall invoice MAP for MAP’s portion of ALLERGAN Patent Expenses in
arrears on a Calendar Quarter basis. ALLERGAN’s invoice shall be in a form reasonably specified by MAP and include a detailed accounting of the ALLERGAN Patent Expenses incurred by ALLERGAN during the relevant Calendar Quarter. Unless MAP
disputes the 

  
 35 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
invoiced amounts, MAP shall remit payment to ALLERGAN of the full invoice amount within [***] of receipt thereof. 
 10.5    Third Party Infringement Claims. 

(a)       Notice.   If the Development, Manufacture, import, use, Commercialization or
sale of Product in the Field in the Territory results in a claim by a Third Party alleging infringement of a Patent owned or controlled by such Third Party (“Third Party Claim”), the Party first having notice of such claim shall
promptly notify the other Party in writing. The notice shall set forth the facts of the Third Party Claim in reasonable detail. 

(b)       Defense.   MAP shall be responsible for defending any Third Party Claim, but
shall consult with ALLERGAN regarding the strategy for such defense and keep ALLERGAN apprised of the status of, and substantive developments in, the case. To the extent related to Product Commercialized to Physician Targets for use in the Field and
solely and specifically in the Territory, and with the exception of Excluded Claims, all reasonable outside counsel costs and expenses of defending such Third Party Claims shall be “Defense Expenses” and included in Shared Expenses
as set forth in Exhibit 1.113, subject to the provisions of Exhibit 1.113. For the avoidance of doubt, any settlement costs and expenses and any damages resulting from Third Party Claims shall not be Defense Expenses. In the event that ALLERGAN
is named as a defendant in such litigation, counsel representing MAP shall also represent ALLERGAN to the extent permitted under Applicable Laws. In the event that separate counsel is required to avoid a conflict of interest, ALLERGAN shall be
permitted to select counsel for such defense subject to MAP’s reasonable approval and all reasonable costs and expenses of such separate counsel for defending such Third Party Claims shall be Defense Expenses included in Shared Expenses as set
forth in Exhibit 1.113; provided, however, that if ALLERGAN retains separate counsel not required by a conflict, the costs and expenses of such separate counsel are paid solely by ALLERGAN. [***]. 

10.6    Enforcement of MAP Patent Rights Against Third Parties. 

(a)       Each Party shall notify the other Party promptly of any conduct on the part of a Third Party that
it reasonably believes may be a potential infringement of MAP Patent Rights in the Field in the Territory, including the facts of such alleged infringement in reasonable detail. The Parties shall thereafter reasonably cooperate to promptly determine
whether and the extent of any such infringement. 
 (b)       MAP shall have the first right, but
not the obligation, to enforce MAP Patent Rights against any such infringing activities. If MAP fails to initiate litigation or take steps to abate such infringement with respect to Product Specific Patent Rights within [***] of a written request by
ALLERGAN to do so, ALLERGAN, in its discretion, may undertake such action as it deems necessary to enforce the Product Specific Patent Rights in the Field in the Territory. 
 (c)       Each Party agrees to cooperate fully and provide each other with information or assistance that the other Party may reasonable request in connection with any

  
 36 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
litigation initiated pursuant to this Section, including voluntarily consenting to be named as a plaintiff in an action commenced by the other Party. 

(d)     The Party initiating the action under Section 10.6(b) shall have control over the handling of the
litigation, including the selection of counsel and settlement; provided, however, that no Party shall settle any action in a manner that will substantively adversely affect the rights of the other Party (including without limitation the licenses
granted herein) without the consent of such other Party, which consent shall not unreasonably be withheld and, further provided that such other Party shall have the right, at its expense (except in the case of a conflict), to be represented in such
action by separate counsel of its own choice. The Party controlling such litigation shall keep the other Party reasonably informed about the status and developments in such action, including considering, in good faith, the input of the other Party
regarding the strategy and handling of the litigation. 
 (e)     All reasonable outside counsel fees and
expenses (including expert fees and expenses, but excluding the costs of non-conflicted, separate counsel of a Party) of any action initiated in accordance with Section 10.6(b) incurred by MAP or ALLERGAN shall be “Patent Litigation
Expenses” and included in Shared Expenses as set forth in Exhibit 1.113, subject to the terms thereof. All recoveries, lump-sum settlements, royalty payments or other consideration received by the Parties as a result of any such
litigation or settlement of any infringement (directed by either Party) shall be deemed to be Net Sales included in the calculation of Distributable Profit and shared as set forth in Section 8.3. 

10.7    Notice of Third Party Infringement Litigation.   In any action by or against MAP involving
any of the MAP Patent Rights that may potentially impact the MAP Patent Rights in the Field in the Territory, MAP shall promptly keep ALLERGAN advised of the status of, and substantive developments (including without limitation, settlement offers
and discussions) in, such action with sufficient advance notice, to the extent reasonably practical, for ALLERGAN to provide substantive input regarding the strategy and handling of such actions. 

10.8    Further Actions.   Each Party shall cooperate with the other Party to execute documents and
take actions as reasonably requested to effect the intent of this Article 10. [***], during the term of this Agreement, comply with all of its material obligations under, [***]. For the avoidance of doubt, any breach or failure [***]. 

11.    TRADEMARKs. 
 11.1    To the extent allowed by Applicable Laws and consistent with each Party’s internal Trademark policy as to size, location and prominence, any Promotional Materials
shall carry in a designated location the MAP Trademarks and ALLERGAN Trademarks in equal size, except for Product Trademark (LEVADEX or any other Product Trademark the Parties might agree upon), which shall be larger, subject to the JCC’s
approval of the size, position, and location thereof on Product or its components. Further, at MAP’s request, such Promotional Materials associated with Product shall carry, in a reasonable location, form, and font as designated by the
JCC, a Patent notice in accordance with and when required by the Applicable Laws of the country in which (i) Product is sold, and (ii) a claim in a Patent included in the MAP Patent Rights. MAP agrees that it shall not use any Trademark on
Product or any Promotional 

  
 37 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Materials other than the MAP Trademarks, ALLERGAN Trademarks or, as required by the Nektar License, the Nektar Trademarks. MAP covenants and agrees that any patent notices that MAP includes on
any packaging or Promotional Materials in accordance with Section 11.1 shall be, at the time distributed by ALLERGAN, accurate and shall cover the product(s) marked. 
 11.2     MAP grants to ALLERGAN the right to use MAP Trademarks and, to the extent necessary and requested by MAP, the right to use the Nektar Trademarks (and subject to the
requirement to use the Nektar Trademarks with respect to Product as provided in the Nektar License), solely to exercise ALLERGAN’s rights and fulfill its obligations set forth in this Agreement. ALLERGAN shall not use any MAP Trademark outside
the scope of this Agreement, or take any action that would materially adversely affect the value of any MAP Trademark. MAP shall retain the right to monitor the quality of the goods on or with which the MAP Trademark is used as necessary to maintain
its trademark rights. ALLERGAN shall not use any MAP Trademark in packaging materials, package inserts, labels, labeling, and marketing, sales, advertising and promotional materials except as approved in accordance with this Agreement and the
Co-Promotion Agreement. 
 11.3     ALLERGAN grants to MAP the right to use the ALLERGAN Trademarks
solely to the extent necessary for MAP to exercise its rights and fulfill its obligations set forth in this Agreement. MAP shall not use any ALLERGAN Trademark outside the scope of this Agreement, or take any action that would materially adversely
affect the value of any ALLERGAN Trademark. ALLERGAN shall retain the right to monitor the quality of the goods on or with which the ALLERGAN Trademark is used as necessary to maintain its trademark rights. MAP shall not use any ALLERGAN Trademark
in packaging materials, package inserts, labels, labeling, and marketing, sales, advertising and promotional materials except as approved in accordance with this Agreement and the Co-Promotion Agreement. 

12.    REPRESENTATIONS AND WARRANTIES. 

12.1     The Parties’ Representations and Warranties.   Each Party hereby represents, warrants
and covenants to the other Party, as of the Effective Date, as set forth below: 
 (a)     Such Party
(i) is a corporation duly organized and validly existing under the laws of its jurisdiction of organization, and (ii) has full power and authority and the legal right to own and operate its property and assets and to carry on its business
as it is now being conducted and as it is contemplated to be conducted by this Agreement; 
 (b)     Such
Party has sufficient legal and/or beneficial title under its intellectual property rights necessary for the purposes contemplated under this Agreement and to grant the license contained in this Agreement; 

(c)     Such Party is not aware of any pending or threatened litigation, nor has it received any notice of claim,
alleging that it has violated or would violate, through the manufacture, import and/or sale of Product hereunder, or by conducting its obligations as currently proposed under this Agreement, any intellectual property or other rights of any Third
Party; 

  
 38 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (d)     To such Party’s knowledge, all of its employees, officers,
independent contractors, consultants and agents have executed agreements requiring assignment to such Party of all inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as
confidential the Confidential Information of such Party; 
 (e)     Such Party has the power, authority and
legal right, and is free to enter into this Agreement and, in so doing, will not violate any other agreement to which such Party is a party as of the Effective Date and such Party has maintained and will maintain and keep in full force and effect
all agreements and regulatory filings necessary to perform its obligations under the Agreement. Moreover, during the Term, such Party shall not enter into any agreement with a Third Party that will conflict with the rights granted to the other Party
under this Agreement; 
 (f)     This Agreement has been duly executed and delivered on behalf of such Party
and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of
creditor rights and judicial principles affecting the availability of specific performance and general principles of equity; 

(g)     Such Party has taken all corporate action necessary to authorize the execution, delivery and performance of
this Agreement; 
 (h)     Except in connection with or related to the settlement between ALLERGAN and the
United States Department of Justice, announced on September 1, 2010, neither such Party, nor any of such Party’s employees, officers, independent contractors, consultants or agents who will render services relating to Product: (i) has
ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a; or (ii) has ever been under indictment for a crime for which a person or entity could be
debarred under said Section 335a. If during the Term a Party has reason to believe that it or any of its employees, officers, independent contractors, consultants or agents rendering services relating to Product: (x) is or will be debarred
or convicted of a crime under 21 U.S.C. Section 335a; or (y) is or will be under indictment under said Section 335a, then such Party shall immediately notify the other Party of same in writing; 

(i)     Such Party has obtained all necessary consents, approvals and authorizations of all Regulatory Authorities
and other Third Parties required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder; and 

(j)     The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder:
(i) do not conflict with or violate any provision of the certificate of incorporation, bylaws, limited partnership agreement or any similar instrument of such Party, as applicable, in any material way; (ii) to such Party’s knowledge,
do not conflict with, violate or breach or constitute a default or require any consent under any indenture, mortgage, contract or instrument to which it is party or by which it is bound; and (iii) to such Party’s knowledge, do not conflict
with, violate, or breach or constitute a default or require any 

  
 39 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
consent under, any requirement of Applicable Laws or court or administrative order by which such Party is bound. 
 12.2    Representations and Warranties of ALLERGAN.   ALLERGAN hereby represents, warrants and covenants to MAP that, as of the Effective Date, as set forth below:

 (a)     Exhibit 1.7 sets forth a true and complete list of the ALLERGAN Trademarks. 

(b)     Nothing in the settlement between ALLERGAN and the United States Department of Justice, announced on
September 1, 2010, conflicts with ALLERGAN’s ability to enter into this Agreement and perform its obligations hereunder. 
 12.3    Representations and Warranties of MAP.   MAP hereby represents and warrants and covenants to ALLERGAN, as of the Effective Date, as set forth below:

 (a)     other than the license granted hereunder, it [***] to all right, title and interest, in, to and
under the MAP Licensed Intellectual Property in the Territory; 
 (b)     MAP has sufficient rights to grant
the licenses and rights granted herein, free and clear of any security interests, claims, encumbrances or charges of any kind that would conflict in any material respect with the rights granted hereunder; 

(c)     MAP has not assigned or granted licenses, nor shall MAP assign or grant licenses or rights, to the MAP
Licensed Intellectual Property to any Third Party that would conflict in any material respect with the rights granted hereunder; 
 (d)     other than as set forth in this Agreement, MAP [***] in connection with MAP’s research, development and manufacturing of the Product, and consistent with the terms and
intent of this Agreement; 
 (e)     MAP [***] to all right, title and interest, in, to under the MAP
Licensed Intellectual Property incorporated in or used in Manufacturing Product; 
 (f)     to MAP’s
knowledge, the Commercialization or Manufacture, use, sale, offering for sale, import, export and other exploitation of Product in the Field in the Territory (and Development in Canada, if applicable) [***] any Patent or other intellectual property
rights of any Third Party; 
 (g)     to MAP’s knowledge, the issued Patents within the MAP Patent
Rights in the Territory [***]; 
 (h)     MAP has obtained [***] assignment of all right, title and interest
in the MAP Device Patent Rights and the Product Specific Patent Rights in the Territory, [***] except as would not have a material adverse effect on Commercialization of Product; 

  
 40 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (i)     all applicable maintenance and renewal fees (including with
respect to designation of small entity status) with respect to the MAP Patent Rights in the Territory have been paid and all documents, and certificates required to be filed for the purpose of maintaining such Patent Rights have been filed;

 (j)     to MAP’s knowledge, all applicable [***] during prosecution by MAP of the MAP Patent Rights;

 (k)     to MAP’s knowledge, no Third Party has asserted that any MAP Licensed Intellectual Property
is invalid or not enforceable; 
 (l)     none of the MAP Device Patent Rights or the Product Specific
Patent Rights and, to MAP’s knowledge, the Nektar Patent Rights, were developed with federal or state funding from any Governmental Authority such that any Governmental Authority has any march-in rights or other rights to use the MAP Licensed
Intellectual Property in the Field in the Territory; 
 (m)     to MAP’s knowledge, no Third Party has
infringed or misappropriated the MAP Licensed Intellectual Property; 
 (n)     the MAP Licensed
Intellectual Property licensed hereunder constitutes all of the intellectual property rights Controlled by MAP that are [***] for ALLERGAN to Commercialize Product in the Field in the Territory; 

(o)     Exhibit 1.34 sets forth a true and complete description of the Device; 

(p)     a true and correct copy of the Nektar License, including all applicable amendments, have been provided to
ALLERGAN, such License is in full force and effect pursuant to its written terms, and [***]; and 
 (q)
    to MAP’s knowledge, MAP has complied in all material respects with all Applicable Laws in the prosecution and maintenance of the MAP Patent Rights in the Territory. 

13.    NON-SOLICITATION OF
EMPLOYEES. 
 13.1    Non-Solicitation.   During the Term
and for a period of [***] thereafter, neither Party shall, without the express written consent of the other Party, recruit, solicit or induce any employee of the other Party to terminate his or her employment with such other Party. The foregoing
provision shall not, however, restrict either Party or its Affiliates from advertising employment opportunities in any manner that does not directly target the other Party or its Affiliates or from hiring any persons who respond to such generalized
advertisements. 
 14.    MUTUAL INDEMNIFICATION AND
INSURANCE. 
 14.1    MAP’s Right to
Indemnification.   Subject to the provisions of this Agreement, ALLERGAN shall indemnify, defend and hold harmless MAP and its Affiliates, and their respective employees, officers, independent contractors, consultants or agents, and
their 

  
 41 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
respective successors, heirs and assigns and representatives (the “MAP Indemnitees”), from and against any and all claims, threatened claims, damages, losses, suits, proceedings,
liabilities, costs (including without limitation reasonable legal expenses, costs of litigation and reasonable attorneys’ fees) or judgments, whether for money or equitable relief, of any kind (“Losses and Claims”), to the
extent arising out of or relating to, directly or indirectly: (a) the negligence, recklessness or wrongful intentional acts or omissions of ALLERGAN, its Affiliates and/or its Sublicensees and its or their respective employees, officers,
independent contractors, consultants or agents, in connection with ALLERGAN’s performance of its obligations or exercise of its rights under this Agreement; (b) any breach by ALLERGAN of any representation, warranty, covenant or obligation
set forth in this Agreement; and/or (c) the Development and/or Commercialization (including without limitation promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, labeling, handling
storage, use of, exposure to any Product actually conducted by or for ALLERGAN or any of its Affiliates, Sublicensees, agents and independent contractors (in each case, excluding any Development or Commercialization activities carried out by and/or
on behalf of MAP hereunder); except in each such case for Losses and Claims to the extent reasonably attributable to any negligence, recklessness, willful misconduct or breach of this Agreement by MAP or a MAP Indemnitee. 

14.2     ALLERGAN’s Right to Indemnification.   Subject to the provisions of this Agreement,
MAP shall indemnify, defend and hold harmless ALLERGAN and its Affiliates, and their respective employees, officers, independent contractors, consultants or agents, and their respective successors, heirs and assigns and representatives (the
“ALLERGAN Indemnitees”), from and against any and all Losses and Claims, to the extent arising out of or relating to, directly or indirectly: (a) the negligence, recklessness or wrongful intentional acts or omissions of MAP,
its Affiliates and/or its Sublicensees and its or their respective employees, officers, independent contractors, consultants or agents, in connection with MAP’s performance of its obligations or exercise of its rights under this Agreement;
(b) any breach by MAP of any representation, warranty, covenant or obligation set forth in this Agreement; and/or (c) the Development and/or Commercialization (including without limitation promotion, advertising, offering for sale, sale or
other disposition), transfer, importation or exportation, labeling, handling storage, use of, exposure to any Product actually conducted by or for MAP or any of its Affiliates, Sublicensees, agents and independent contractors (in each cases,
excluding any Development or Commercialization activities carried out by and/or on behalf of ALLERGAN hereunder); (d) any allegation that the making, having made, use, sale, offering for sale, import or export of the Product violates, infringes
upon, or misappropriates the intellectual property rights of any Third Party (provided, however, that MAP shall not be required to hold ALLERGAN harmless from [***] that are included in [***]; and (e) any [***] that personal injury or death, or
any damage to any property, was caused or allegedly caused by a defect in any Product manufactured by or for MAP; except in each such case for Losses and Claims to the extent reasonably attributable to any negligence, recklessness, willful
misconduct or breach of this Agreement by ALLERGAN or an ALLERGAN Indemnitee. 
 14.3     Process for
Indemnification.   A Party’s obligation to defend, indemnify and hold harmless the other Party under this Article 14 shall be conditioned upon the following: 

  
 42 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a)     A Party seeking indemnification under this Article 14 (the
“Indemnitee”) shall give prompt written notice of the claim to the other Party (the “Indemnitor”). Failure to promptly notify the Indemnitor of any such claim shall not relieve the Indemnitor of any such duty to so
indemnify except to the extent that the Indemnitor can demonstrate actual loss and prejudice as a result of such failure. 

(b)     Each Party shall furnish promptly to the other Party copies of all papers and official documents received in
respect of any Losses and Claims. Failure to promptly furnish the other Party with such papers and official documents shall not relieve the other Party of any duty to indemnify except to the extent that the other Party can demonstrate actual loss
and prejudice as a result of such failure. The Indemnitee shall cooperate as requested by the Indemnitor in the defense against any Losses and Claims. 
 (c)     The Indemnitor shall have the right to assume and control the defense of the indemnification claim, including any settlement of such claim, at its own expense with counsel
selected by the Indemnitor and reasonably acceptable to the Indemnitee. The Indemnitor shall not settle or compromise the indemnification claim in any manner which would have an adverse effect on the Indemnitee’s interests (including without
limitation any rights under this Agreement or the Co-Promotion Agreement or the scope or enforceability of the MAP Patent Rights or MAP Know-How, or Confidential Information or Patent or other rights licensed to ALLERGAN by MAP hereunder), without
the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld, delayed or conditioned. The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s expense and shall make
available to the Indemnitor all pertinent information under the control of the Indemnitee. 
 (d)     The
Indemnitor shall not be liable for any settlement or other disposition of Losses and Claims by the Indemnitee which is reached without the written consent of the Indemnitor. 
 14.4    Insurance. 
 (a)     During
the Term and for [***] thereafter, ALLERGAN shall maintain, at its sole expense subject to Section 4.5 with respect to Allowable Development Expenses, such types and amounts of insurance coverage relating to Product liability (including without
limitation, premises operations, completed operations and broad form contractual liability) that is comparable in type and amount to the insurance customarily maintained by pharmaceutical companies with respect to similar prescription pharmaceutical
products that are marketed, distributed and sold in the Territory, and which names MAP as an additional insured Party, as its interests may appear. 
 (b)     During the Term and for [***] thereafter, MAP shall maintain, at its sole expense subject to Section 4.5 with respect to Allowable Development Expenses, such types and
amounts of insurance coverage relating to Product liability (including without limitation, premises operations, completed operations and broad form contractual liability) and applicable clinical trial coverage, that is comparable in type and amount
to the insurance customarily maintained by pharmaceutical companies with respect to similar prescription pharmaceutical 

  
 43 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
products that are marketed, distributed and sold in the Territory, and which names ALLERGAN as an additional insured Party, as its interests may appear. 

15.    CONFIDENTIALITY. 

15.1     Confidentiality.   During the Term and for a period of [***] thereafter, each Party shall
maintain in confidence all Information and materials of the other Party disclosed or provided to it by the other Party (either pursuant to this Agreement, or the Confidential Disclosure Agreement entered into by the Parties dated October 27,
2009 (the “Confidential Disclosure Agreement”)) (together with all embodiments thereof, the “Confidential Information”). Confidential Information also includes Information generated hereunder, and Information
regarding intellectual property and confidential or proprietary Information of Third Parties, in each case as described by one Party to the other Party. In addition and notwithstanding the foregoing, any Information under Article 10 constituting
Inventions and discoveries owned by one Party shall be deemed to be Confidential Information disclosed by such Party and received by the other Party, even if such Information is initially generated and disclosed by the other Party. The terms and
conditions of this Agreement and the Confidential Disclosure Agreement shall be deemed Confidential Information of both Parties. 
 15.2     Degree of Care; Permitted Use.   Each Party shall take reasonable steps to maintain the confidentiality of the Confidential Information of the other Party,
which steps shall be no less protective than those steps that such Party takes to protect its own Confidential Information of a similar nature, and in no event less than a reasonable degree of care. Neither Party shall use or permit the use of any
Confidential Information of the other Party except for the purposes of carrying out its obligations or exercising its rights under this Agreement or the Confidential Disclosure Agreement, and neither Party shall copy any Confidential Information of
the other Party except as may be reasonably necessary or useful for such purposes. All Confidential Information of a Party, including without limitation all copies and derivations thereof, is and shall remain, as between the Parties, the sole and
exclusive property of the disclosing Party and subject to the restrictions provided for herein. Neither Party shall disclose any Confidential Information of the other Party to Third Parties, other than to those of its directors, officers,
Affiliates, employees, actual or potential licensors, independent contractors, actual or potential Sublicensees, actual or potential assignees, agents and external advisors directly involved in or concerned with the carrying out of this Agreement,
on a strictly applied “need to know” basis; provided, however, that such persons and entities are subject to confidentiality and non-use obligations at least as stringent as the confidentiality and non-use obligations provided for in this
Article 15. Except to the extent expressly permitted under this Agreement, the receiving Party may not use Confidential Information of the other Party in applying for Patents or securing other intellectual property rights without first consulting
with, and obtaining the written approval of, the other Party (which approval shall not be unreasonably withheld, delayed or conditioned). 
 15.3     Exceptions.   The obligations of confidentiality and non-use set forth in Section 15.2 shall not apply to any portion of Confidential Information that
the receiving Party can demonstrate by contemporaneous written records was: (a) known to the general public at the time of its disclosure to the receiving Party, or thereafter became generally known to the general 

  
 44 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
public, other than as a result of actions or omissions of the receiving Party or anyone to whom the receiving Party disclosed such portion; (b) known by the receiving Party prior to the date
of disclosure by the disclosing Party; (c) disclosed to the receiving Party on an unrestricted basis from a source unrelated to the disclosing Party and not known by the receiving party to be under a duty of confidentiality to the disclosing
Party; or (d) independently developed by the receiving Party by personnel that did not have access to or use of Confidential Information of the disclosing Party. Any combination of features or disclosures shall not be deemed to fall within the
foregoing exclusions merely because individual features are published or known to the general public or in the rightful possession of the receiving Party unless the combination itself are published or known to the general public or are in the
rightful possession of the receiving Party. 
 15.4     Permitted Disclosures.   The
obligations of confidentiality and non-use set forth in Section 15.2 shall not apply to the extent that the receiving Party: (a) is required to disclose Information pursuant to: (i) an order of a court of competent jurisdiction;
(ii) Applicable Laws; (iii) regulations or rules of a securities exchange; (iv) requirement of a governmental agency for purposes of obtaining approval to test or market Product; (v) disclosure of Information to a patent office
for the purposes of filing a Patent as permitted in this Agreement; or (vi) the exercise by each Party of its rights granted to it under this Agreement or its retained rights; or (b) discloses such Confidential Information solely on a
“need to know basis” to Affiliates, potential and future collaborators (including without limitation Sublicensees), potential or actual acquirers, merger partners, licensees, or assignees permitted under Section 18.2, potential or
actual Development collaborators, subcontractors, investment bankers, investors, lenders, or other potential financial partners, and their respective directors, employees, contractors and agents, provided that such Third Party or person or entity in
subsection (b) agrees to confidentiality and non-use obligations with respect thereto at least as stringent as those specified for in this Article 15; provided that, in the case of (a)(i) through (iv), the receiving Party shall provide prior
written notice thereof to the disclosing Party and use reasonable efforts to provide the opportunity for the disclosing Party to review and comment on such required disclosure and request confidential treatment thereof or a protective order
therefor. 
 15.5     Return of Confidential Information.   Each Party shall return or
destroy, at the other Party’s instruction, all Confidential Information of the other Party in its possession upon termination or expiration of this Agreement, or destroy such Confidential Information; provided, however, that each Party shall be
entitled to retain one (1) copy of such Confidential Information of the other Party, (a) to the extent reasonably required to allow the relevant Party to carry out any remaining obligations under this Agreement or the Co-Promotion
Agreement or to exercise any of its rights that expressly survive termination or expiration of this Agreement or the Co-Promotion Agreement, and (b) for legal archival purposes and/or as may be required by Applicable Law. The receiving Party
shall provide a written confirmation of such destruction within thirty (30) days of such destruction. 

15.6     Public Disclosure.   The Parties agree that the initial public announcement of the
execution of this Agreement shall be in the form of the Press Release that describes the nature and scope of the collaboration including its aggregate value, attached to this Agreement as Exhibit 1.96. Unless otherwise required by Applicable Laws,
during the Term, in all cases other 

  
 45 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
than the announcement set forth in the Press Release, each Party shall submit to the other Party for review and approval all proposed press releases, academic, scientific, and medical
publications and public presentations relating to activities performed under this Agreement that have not been previously reviewed and approved or disclosed. Such review and approval shall be conducted for the purposes of preserving intellectual
property protection and determining whether any portion of the proposed publication or presentation containing the Confidential Information of MAP should be modified or deleted, and to determine whether such disclosure is in the best interests of
the Parties in connection with the Development of Product in the Field in the Territory. Written copies of such proposed publications and presentations (other than press releases) shall be submitted to the other Party no later than [***] before
submission for publication or presentation, and the receiving Party shall provide written comments, if any, within [***] of receipt. Unless otherwise required by Applicable Laws, written copies of proposed press releases shall be submitted to the
other Party no later than [***] before release and the receiving Party shall provide written comments, if any, within [***] of receipt. 
 16.    TERM AND TERMINATION. 
 16.1     Effective Date and Term.   The Term shall commence on the Effective Date and shall continue until the later of (a) December 31, 2025, and
(b) the date that the last MAP Patent Right covering Product in the Territory expires, unless earlier terminated in accordance with Article 16 (the “Term”). 

16.2     Termination by ALLERGAN. 
 (a)       After the First Commercial Sale in the Field in the Territory, ALLERGAN shall have the right to terminate this Agreement at will upon one hundred eighty
(180) days’ prior written notice. 
 (b)       After the receipt by MAP of a complete
response letter (or its equivalent) for Product from the FDA which, notwithstanding Section 8.8, in ALLERGAN’s sole discretion made in good faith, would require actions by MAP that would be likely to result in either: (i) ALLERGAN
incurring Development expenses estimated to be in excess of [***] to obtain Initial Indication Approval; or (ii) a delay in the Initial Indication Approval by more than [***] from receipt of such complete response letter (or its equivalent) for
Product from the FDA, ALLERGAN shall have the right to terminate this Agreement at will upon written notice to MAP. 

16.3     Termination by MAP.   If during the Term, ALLERGAN Commercializes a Competing Product in
the Territory, MAP shall have the right to terminate the Agreement upon written notice. 
 16.4    
Termination for Material Breach.   If either Party believes the other is in material breach of its obligations under this Agreement, it may give notice of such breach to the other Party, which Party shall have [***] in which to
remedy such breach, or [***] in the case of material breach of any payment obligation hereunder. Such [***] period shall be extended in the case of a breach not capable of being remedied in such [***] period so long as the breaching Party uses
diligent efforts to remedy such breach and is pursuing a course of action that, if 

  
 46 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
successful, will effect such a remedy; provided, however, that such cure period shall not be extended more than [***]. If such alleged breach is not remedied or is not capable of being remedied
within the period set forth above, the nonbreaching Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this
Agreement upon written notice to the other Party. In the event of a dispute regarding any payments due and owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute
including any accrued interest thereon. 
 16.5     Challenge.   MAP shall have the right
to terminate this Agreement immediately upon written notice if ALLERGAN challenges the validity, scope or enforceability of or otherwise opposes any Patent included in the MAP Patent Rights. If a Sublicensee of ALLERGAN challenges the validity,
scope or enforceability of or otherwise opposes any Patent included in the MAP Patent Rights under which such Sublicensee is sublicensed, then ALLERGAN shall, upon written notice from MAP, terminate such sublicense. ALLERGAN shall include provisions
in all agreements under which a Third Party obtains a license under any Patent included in the MAP Patent Rights providing that if the Sublicensee challenges the validity or enforceability of or otherwise oppose any such Patent under which the
Sublicensee is sublicensed, ALLERGAN may terminate such sublicense. In the event that all or any portion of this Section 16.6 is invalid, illegal or unenforceable, then the Parties will use reasonable efforts to replace the invalid, illegal or
unenforceable provision(s) with valid, legal and enforceable provision(s). 
 16.6     Consequences of
Termination.   In the event that either Party terminates this Agreement, then as of the effective date of such termination, the following terms and conditions shall apply: 

(a)       The license granted in Article 2 shall terminate immediately and all rights with respect thereto
shall revert in their entirety to MAP; 
 (b)       The Co-Promotion Agreement shall automatically
terminate upon termination of this Agreement; and 
 (c)       ALLERGAN shall transfer to MAP,
subject to the provisions of Section 15.5, all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form developed, controlled or generated as of the Effective Date of such
termination by or on behalf of ALLERGAN, its Affiliates or Sublicensees with respect to Product. 

16.7     Surviving Obligations.   Upon termination of this Agreement, the Parties shall remain
obligated to make all payments which have accrued under this Agreement prior to the date of termination, when and as they become due and payable. In addition, the provisions in Article 1 (Definitions), Section 8.7 (Withholding), Article 9
(Record Retention and Audits), Section 10.1 (Existing Intellectual Property), Article 10.2 (Ownership of Inventions), Section 10.5(a) (Notice of Third Party Infringement Claims), Section 10.6(a) (notice of potential infringement),
Article 12 (Representations and Warranties), Article 13 (Non-Solicitation of Employees), Article 14 (Mutual Indemnification and Insurance), Article 15 (Confidentiality), 

  
 47 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Section 16.6 (Consequences of Termination), Section 16.7 (Surviving Obligations), Section 16.8 (Accrued Rights, Surviving Obligations), Article 17 (Limitation of Liability and
Exclusion of Damages; Disclaimer of Warranty), Section 18.5 (Notices), Section 18.7 (Waiver), Section 18.11 (Governing Law), Section 18.12 (Dispute Resolution; Exclusive Dispute Resolution Mechanism) of this Agreement shall
survive termination of this Agreement for any reason. 
 16.8     Accrued Rights, Surviving
Obligations.   Termination or expiration of this Agreement shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. Termination by a Party shall not be an
exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law. 

16.9     Rights in Bankruptcy.   All rights and licenses granted under or pursuant to this Agreement
by MAP or ALLERGAN are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 91 of the United States
Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the United States Bankruptcy Code. The Parties further agree that, in
the event of the commencement of a bankruptcy proceeding by or against either Party under the United States Bankruptcy Code, the Party that is not a party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy
proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under clause (a) above,
following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. 
 17.    LIMITATION OF LIABILITY AND EXCLUSION OF DAMAGES;
DISCLAIMER OF WARRANTY. 
 17.1    
EXCEPT IN THE CASE OF A BREACH OF ARTICLE 15, AND WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER ARTICLE 14, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING
WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS, OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 

17.2     EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, MAP PROVIDES NO WARRANTIES, WHETHER WRITTEN OR ORAL,
EXPRESS OR IMPLIED, REGARDING PRODUCT, COMPOUND, OR THE DEVICE USED IN PRECLINICAL STUDIES OR CLINICAL TRIALS, AND MAP HEREBY DISCLAIMS ALL OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS AND IMPLIED,

  
 48 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND FREEDOM FROM INFRINGEMENT OF THIRD PARTY RIGHTS. 

18.     MISCELLANEOUS. 

18.1     Agency.   Neither Party is, nor shall be deemed to be, an employee, agent, partner or
co-venturer, or legal representative of the other Party for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the other Party, assume any obligations for the other Party or make any
representations or warranties on behalf of that other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 

18.2     Assignment.   Neither this Agreement, nor any of the rights and obligations hereunder shall
be assigned or, except as expressly permitted hereby, delegated, by any Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld, delayed, or conditioned); provided, however, (i) the
assignment of this Agreement by operation of law pursuant to a merger or consolidation of either Party with or into any Third Party shall, regardless of the identity of the surviving entity to such merger or consolidation, be permitted,
(ii) either Party, without such consent, may assign its rights and delegate its obligations hereunder to an Affiliate thereof without obtaining such consent, provided that the assigning Party agrees to remain primarily liable for the full and
timely performance by such Affiliate of all its obligations hereunder, and (iii) either Party, without such consent, may assign its rights and delegate its obligations hereunder to a successor entity or acquirer of such Party or of all or
substantially all of such Party’s business to which this Agreement relates, provided that the assigning Party agrees to remain primarily liable for the full and timely performance by such assignee of all its obligations hereunder. This
Agreement shall be binding upon and inure to the benefit of, the Parties and their respective successors and permitted assignees and the name of a Party appearing herein shall be deemed to include the names of such Party’s successor’s and
permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 18.2 shall be null and void. 
 18.3     Further Actions.   Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be reasonably
necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 18.4    
Force Majeure.   Neither Party shall be liable or responsible to the other Party for loss or damages, nor shall it have any right to terminate this Agreement for any default or delay attributable to any event beyond its
reasonable control and without its fault or negligence, including but not limited to acts of God, acts of government (including injunctions), fire, flood, earthquake, strike, lockout, labor dispute, breakdown of plant, shortage of critical
equipment, loss or unavailability of manufacturing facilities or material, casualty or accident, civil commotion, acts of public enemies, acts or terrorism or threat of terrorist acts, blockage or embargo and the like (a “Force Majeure
Event”); provided, however, that in each such case the Party affected shall use reasonable efforts to avoid such occurrence and to remedy it promptly. 

  
 49 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
The Party affected shall give prompt notice of any such cause to the other Party, which includes all relevant details of the occurrence, and an estimate of how long such Force Majeure event shall
continue. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for thirty (30) days thereafter, and the Party receiving
notice shall be similarly excused from its respective obligations which it is thereby disabled from performing; provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. If such
Force Majeure Event continues for a period of one hundred and eighty (180) days, either Party may terminate the Agreement upon written notice. Notwithstanding the foregoing, nothing in this Section 18.4 shall excuse or suspend the
obligation to make any payment due hereunder in the manner and at the time provided. 
 18.5    
Notices.   All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided that notices of a change of address shall be effective
only upon receipt thereof): 
  

	         If to ALLERGAN, addressed to: 
	ALLERGAN, Inc. 

	 	2525 Dupont Drive 

	 	Irvine, California 92612 

	 	Attn: [***] 

	 	Facsimile: [***] 

	 	Email: [***] 

  

	 	With a copy to: 

  

	 	Gibson, Dunn & Crutcher LLP 

	 	1881 Page Mill Road 

	 	Palo Alto, CA 94304 

	 	Attention: Gregory T. Davidson, Esq. 

	 	Facsimile: (650) 849-5333 

	 	Email: gdavidson@gibsondunn.com 

  

	         If to MAP, addressed to: 
	MAP Pharmaceuticals, Inc. 

	 	2400 Bayshore Parkway, Suite 200 

	 	Mountain View, California 94043 

	 	Attention: [***] 

 Facsimile: [***] 

	 	Email: [***] 

 18.6    
Amendment.   No amendment, modification, or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

  
 50 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 18.7     Waiver.   No provision of this Agreement shall
be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 

18.8     Counterparts.   This Agreement may be executed in two or more counterparts and by facsimile
or other electronic transmission, each of which shall be deemed an original and when taken together shall constitute one and the same instrument. 
 18.9     Construction.   The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of
the provisions of this Agreement. Except where the context otherwise requires, wherever used the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders. The language of this Agreement
shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. 
 18.10     Severability.   Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under Applicable Laws,
but, if any provision of this Agreement is held to be prohibited by or invalid under Applicable Laws or unenforceable by a court of competent jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity,
without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement. 

18.11     Governing Law.   This Agreement shall be governed by and interpreted in accordance with
the substantive laws of the State California without regard to its or any other jurisdiction’s choice of law rules that would result in the application of the laws of any state other than the State of California. 

18.12     Dispute Resolution; Exclusive Dispute Resolution Mechanism. 

(a)     Except to the extent that a Party may be entitled to provisional or preliminary relief and subject to
MAP’s final decision making as set forth in Section 3.2(c), the Parties agree that the procedures set forth in this Section 18.12 shall be the exclusive mechanism for resolving any dispute, controversy, or claim (collectively, a
“Dispute”) between the Parties or concerning this Agreement that may arise from time to time pursuant to this Agreement relating to any Party’s rights and/or obligations hereunder that cannot be resolved through good faith
negotiation between the Parties. 
 (b)     In the event of any Dispute between the Parties, a Party shall
provide the other Party written notice of such Dispute, including reasonable detail of all relevant facts and issues. If such Dispute remains unresolved [***]after such notice, the Dispute shall first be submitted to the Executives of each of the
Parties, who shall promptly meet and discuss such Dispute. If such Executives do not resolve a Dispute within [***] after such submission, such Dispute, except with respect to any and all issues regarding the scope, construction, validity, and/or
enforceability of Patents or Patent Applications (which shall be resolved by a court of 

  
 51 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
competent jurisdiction in the country issuing such Patent or in which such Patent Application is filed) shall be exclusively and finally resolved by binding arbitration. 

(c)     Any arbitration concerning a Dispute shall be conducted in Los Angeles, California, United States of America,
unless otherwise agreed to by the Parties in writing. The arbitration shall be conducted by JAMS pursuant to the then-current Comprehensive Arbitration Rules of JAMS. In the event of the Dispute involves a claim of less than or equal [***]
(exclusive of interest and attorney fees and costs), the arbitration shall be conducted by a single arbitrator. In the event of a Dispute involving a claim of greater than [***], the arbitration shall be decided by a panel of three arbitrators, with
one arbitrator selected by each Party and the third arbitrator (who shall be the Chairperson of the arbitration) being selected by the Party arbitrators. The sole arbitrator or Party-selected arbitrators, as applicable, shall be selected within
[***] after receipt by the other Party of the filed Notice of Arbitration. The sole or third arbitrator, as applicable, shall be a retired or former district court or appellate court judge of any United States District Court or United States Court
of Appeals. The sole arbitrator or Chairperson, as applicable, shall reasonably limit the discovery, including document requests, that may be permitted to the information most relevant to the Dispute, recognizing that the Parties have agreed to
arbitration so that there will be a cost-effective resolution of the Dispute on an expedited basis. The Federal Rules of Evidence shall govern the admissibility of evidence during the arbitration. The arbitrator(s) will have no authority to award
punitive or other damages not measured by the prevailing Party’s actual damages, except as may be authorized by Applicable Laws. The determination of the arbitrator(s) shall be final and binding on the Parties and a judgment on such award or
determination may be entered in any court of competent jurisdiction and such judgment shall be final and non-appealable. The decision and award of the arbitrator(s) shall be in writing and accompanied by a reasoned opinion, setting forth the
applicable facts and law supporting the decision, and shall be delivered within [***] following the conclusion of any arbitration. 
 (d)     Each Party shall bear its own costs and attorney’s fees (including expert fees and costs), and the Parties shall equally bear the fees, costs, and expenses of the
(i) arbitration proceedings and (ii) sole arbitrator or Chairperson (in the event of a three-panel arbitration), as applicable; provided, however, that the arbitrator(s) may exercise discretion to award costs, including attorney’s
fees and costs (including expert fees and costs), and the costs of the arbitration proceedings (including any arbitrator(s) fees and costs), to the prevailing Party. 
 18.13     Compliance with Applicable Laws.   Each Party will comply with all Applicable Laws, including, where applicable, then-current Good Laboratory Practices, and
then-current Good Manufacturing Practices, and then-current Good Clinical Practices, in performing its obligations and exercising its rights hereunder, including without limitation the performance of activities connected with the Development,
manufacture, and Commercialization (as applicable) of Product under this Agreement. Nothing in this Agreement shall be deemed to permit ALLERGAN to export, re-export or otherwise transfer any Information transferred hereunder or Product manufactured
therefrom without complying with Applicable Laws. 
 18.14     Divestitures.  
Notwithstanding any other provision of this Agreement, in no event shall ALLERGAN or any of its Affiliates be required to (i) agree or proffer to divest or 

  
 52 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
hold separate (in a trust or otherwise), or take any other action with respect to, any of the assets or businesses of ALLERGAN or any of its Affiliates, or (ii) enter into any agreement that
in any way limits the ownership or operation of any business of ALLERGAN or any of its Affiliates. 

18.15     Entire Agreement.   This Agreement, the Co-Promotion Agreement and the Exhibits, schedules
and other attachments hereto, constitute and contain the complete, final and exclusive understanding and agreement of the Parties, and cancel and supersede any and all prior and contemporaneous negotiations, correspondence, understandings and
agreements, whether oral or written, between the Parties respecting the subject matter hereof, and neither Party shall be liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except as
specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any Party, other than the Parties and their respective successors and assigns, any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided herein. 
 [Signature Page Follows] 

  
 53 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 In Witness Whereof, the Parties have as of the Effective Date duly executed this
Agreement. 
  

									
	ALLERGAN, INC.	 		 	MAP PHARMACEUTICALS, INC.
					
	By:	 	/s/ David E.I. Pyott	 		 	By:	 	/s/ Timothy S. Nelson
					
	Name:	 	David E.I. Pyott	 		 	Name:	 	Timothy S. Nelson
					
	Title:	 	Chairman of the Board and Chief Executive Officer	 		 	Title:	 	President and CEO
			
	ALLERGAN USA, INC.	 		 	
					
	By:	 	/s/ David E.I. Pyott	 		 		 	
					
	Name:	 	David E.I. Pyott	 		 		 	
					
	Title:	 	Chief Executive Officer	 		 		 	
			
	ALLERGAN SALES, LLC	 		 	
					
	By:	 	/s/ David E.I. Pyott	 		 		 	
					
	Name:	 	David E.I. Pyott	 		 		 	
					
	Title:	 	Chief Executive Officer	 		 		 	

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.7 
 ALLERGAN TRADEMARKS* 
  

	1.	ALLERGAN 

  

	2.	ALLERGAN & logo 

  

	*	ALLERGAN Trademarks may be updated by ALLERGAN from time to time and must be approved by ALLERGAN prior to use in connection with any Product or any Promotional
Materials. 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.29 
 CO-PROMOTION AGREEMENT 
 (See Attached) 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.34 
 DEVICE 
 [***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.35 
 DIHYDROERGOTAMINE 
 Structural Formula 

[***] 
 Molecular Formula 

[***] 
 Relative Molecular Mass

 [***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.63(a) 

MAP PATENT RIGHTS: [***]  
 [***] 
  

											
	Country	 	Filing Date	 	Serial No.	 	Issue Date	 	Patent No.	 	Status

[***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.63(b) 

MAP PATENT RIGHTS: [***] 
 [***] 
  

											
	Country	 	Filing Date	 	Serial No.	 	Issue Date	 	Patent No.	 	Status

[***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.63(c) 

MAP PATENT RIGHTS: [***] 
 [***] 
  

											
	Country	 	Filing Date	 	Serial No.	 	Issue Date	 	Patent No.	 	Status

[***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.67 
 MAP TRADEMARKS 
  

											
	Mark	 	Serial No.	 	Registration
No.	 	Country	 	Class	 	Status

[***] 
  

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.96 
 PRESS RELEASE 
 (See Attached) 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.113 
 SHARED EXPENSES 
 [***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 6.2(B) 

SIGNING DATE TRX FORECAST 
 [***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 8.3 
 EXAMPLE OF PROFIT SHARE CALCULATION UNDER SECTION 8.3 
 Examples (the following table is
for illustration purposes only and makes no representation to the accuracy of the assumptions): 
 In accordance with
Section 8.5, the Distributable Loss or Distributable Profit Report shall include a statement of any amount owed by one Party to the other Party (“Net Payment”), to be determined and illustrated as follows: 

(i) If the Distributable Profit is greater than zero (0), MAP shall pay to ALLERGAN an amount equal to ALLERGAN Shared Expenses plus
fifty percent (50%) of the Distributable Profit. For example: 
  

													
	 	  	        MAP        
	 	 	    ALLERGAN    	 	 	        Total        
	 
	 Net Sales
	  	$	800	  	 	$	0	  	 	$	800	  
	 Shared Expenses
	  	 	(300	) 	 	 	(200	) 	 	 	(500	) 
		  	 	 	 	 	 	 	 	 	 	 	 
	 Total Distributable Profit/(Loss) Before Net Payment Adjustment
	  	$	500	  	 	$	(200	) 	 	$	300	  
		  	 	 	 	 	 	 	 	 	 	 	 

  

													
	 Payment of ALLERGAN Shared Expenses
	  				 	$	            200	  	  			
	 Payment of 50% of Total Distributable
Profit (300 x .50)
	  				 	 	150	  	  			
		  	 	 	 	 	 	 	 	  			
	 Net Payment from MAP to ALLERGAN
	  	 	(350	) 	 	 	350	  	  			
		  	 	 	 	 	 	 	 	  			
	 Total Distributable Profit After Net Payment
Adjustment
	  	$	            150	  	 	$	150	  	  	$	            300	  
		  	 	 	 	 	 	 	 	  	 	 	 

 (ii) If the Distributable Profit is equal to zero, MAP shall pay to ALLERGAN an amount equal to the ALLERGAN
Shared Expenses. For example: 
  

													
	 	  	        MAP        
	 	 	    ALLERGAN    	 	 	        Total        
	 
	 Net Sales
	  	$	800	  	 	$	0	  	 	$	800	  
	 Shared Expenses
	  	 	(500	) 	 	 	(300	) 	 	 	(800	) 
		  	 	 	 	 	 	 	 	 	 	 	 
	 Total Distributable Profit/(Loss) Before Net Payment
Adjustment
	  	$	300	  	 	$	(300	) 	 	$	0	  
		  	 	 	 	 	 	 	 	 	 	 	 
	 Payment of ALLERGAN Shared Expenses
	  	 	—	  	 	 	300	  	 			

  
 66 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

													
		  	 	 	 	 	 	 	 	  			
	 Net Payment from MAP to ALLERGAN
	  	 	(300	) 	 	 	300	  	  			
		  	 	 	 	 	 	 	 	  			
	 Total Distributable Profit After Net Payment
Adjustment
	  	$	            0	  	 	$	            0	  	  	$	            0	  
		  	 	 	 	 	 	 	 	  	 	 	 

 (iii) If there is Distributable Loss, and: 

A.     If the MAP Operating Loss is greater than the ALLERGAN Shared Expenses, then ALLERGAN shall pay to MAP
an amount equal to the difference between 50% of the Distributable Loss and the ALLERGAN Shared Expense. For Example: 
 MAP
Operating Loss > ALLERGAN Shared Expenses 

                       
   $300 > $200 
  

													
	 	  	        MAP        
	 	 	    ALLERGAN    	 	 	        Total        
	 
	 Net Sales
	  	$	400	  	 	$	0	  	 	$	400	  
	 Shared Expenses
	  	 	(700	) 	 	 	(200	) 	 	 	(900	) 
		  	 	 	 	 	 	 	 	 	 	 	 
	 Total Distributable Loss Before Net Payment Adjustment
	  	$	(300	) 	 	$	(200	) 	 	$	(500	) 
		  	 	 	 	 	 	 	 	 	 	 	 
				
	 Difference Between:
	  				 				 			
				
	 50% of Total Distributable Loss (500 x .50), and
	  	$	250	  	 				 			
	 ALLERGAN Shared Expenses
	  	 	200	  	 				 			
		  	 	 	 	 	 	 	 	 			
	 Net Payment from ALLERGAN to MAP
	  	 	50	  	 	 	(50	) 	 			
		  	 	 	 	 	 	 	 	 			
	 Total Distributable Loss After Net Payment Adjustment
	  	$	(250	) 	 	$	(250	) 	 	$	(500	) 
		  	 	 	 	 	 	 	 	 	 	 	 

 B.     If the MAP Operating Loss is less than the ALLERGAN Shared Expenses, then
MAP shall pay to ALLERGAN an amount equal to the difference between 50% of the Distributable Loss and the ALLERGAN Shared Expenses. For Example: 
 MAP Operating Loss < ALLERGAN Shared Expenses 

                       
   $200 < $300 
  

													
	 	  	        MAP        
	 	 	    ALLERGAN    	 	 	        Total        
	 
	 Net Sales
	  	$	400	  	 	$	0	  	 	$	400	  
	 Shared Expenses
	  	 	(600	) 	 	 	(300	) 	 	 	(900	) 
		  	 	 	 	 	 	 	 	 	 	 	 
	 Total Distributable Loss Before Net Payment Adjustment
	  	$	(200	) 	 	$	(300	) 	 	$	(500	) 
		  	 	 	 	 	 	 	 	 	 	 	 

 Difference Between: 

  
 67 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

													
	 50% of Total Distributable Loss (500 x .50), and
	  				 	$	250	  	 			
	 ALLERGAN Shared Expenses
	  	 	—	  	 	 	300	  	 			
		  	 	 	 	 	 	 	 	 			
	 Net Payment from MAP to ALLERGAN
	  	 	(50	) 	 	 	50	  	 			
		  	 	 	 	 	 	 	 	 			
	 Total Distributable Loss After Net Payment Adjustment
	  	$	            (250	) 	 	$	            (250	) 	 	$	            (500	) 
		  	 	 	 	 	 	 	 	 	 	 	 

 C.     If there is a MAP Operating Profit, then MAP shall pay to ALLERGAN an
amount equal to the difference between 50% of the Distributable Loss and the ALLERGAN Shared Expenses. For Example: 
  

													
	 	  	        MAP        
	 	 	    ALLERGAN    	 	 	        Total        
	 
	 Net Sales
	  	$	600	  	 	$	0	  	 	$	600	  
	 Shared Expenses
	  	 	(400	) 	 	 	(300	) 	 	 	(700	) 
		  	 	 	 	 	 	 	 	 	 	 	 
	 Total Distributable Loss Before Net Payment Adjustment
	  	$	200	  	 	$	(300	) 	 	$	(100	) 
		  	 	 	 	 	 	 	 	 	 	 	 
	 Difference Between:
	  				 				 			
				
	 50% of Total Distributable Loss (100 x .50), and
	  				 	$	50	  	 			
	 ALLERGAN Shared Expenses
	  				 	 	300	  	 			
		  	 	 	 	 	 	 	 	 			
	 Net Payment from MAP to ALLERGAN
	  	 	(250	) 	 	 	250	  	 			
		  	 	 	 	 	 	 	 	 			
	 Total Distributable Loss After Net Payment Adjustment
	  	$	(50	) 	 	$	(50	) 	 	$	(100	) 
		  	 	 	 	 	 	 	 	 	 	 	 

  
 68 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 
 EXHIBIT 8.5 
 EXAMPLE OF NET SALES CALCULATION 

[***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]